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Androgen deprivation therapy (ADT) has been 
the standard treatment approach for advanced 
prostate cancer for decades. Despite a good initial 
response rate, many patients are likely to experi-
ence a disease relapse within a few years and 
to experience significant adverse effects with a 
deterioration of quality of life (QoL) from ADT.  
  The FinnProstate Study VII (FPVII) was conduct-
ed as a randomised, controlled, multicenter clinical 
trial to compare intermittent (IAD) and continuous 
androgen deprivation  (CAD) in patients with ad-
vanced prostate cancer in terms of time to progres-
sion, overall survival, cancer-specific survival, time 
to treatment failure, and quality of life.
   No difference emerged in progression or 
survival rates between IAD and CAD among the 
randomised 554 patients. However, QoL seemed 
to be better with IAD than CAD, especially in the 
domains of activity limitation, physical capacity, 
and sexual functioning.
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ABSTRACT 
 
Androgen deprivation therapy (ADT) has been the standard treatment for advanced 
prostate cancer (PC) since the 1940s. However, ADT use is associated with adverse effects 
which have an impact on the patient's quality of life (QoL). Furthermore, the duration of 
response of PC to ADT is limited, leading to disease progression with time. 
The FinnProstate Study VII (FPVII) was planned as a randomised, controlled, 
multicenter clinical trial to compare the efficacy of intermittent androgen deprivation (IAD) 
with continuous androgen deprivation (CAD) in treatment of advanced PC with time to 
progression as the primary endpoint. Secondary objectives were to compare treatment arms 
in terms of overall survival (OS), PC-specific survival (PCS), time to treatment failure (TTF), 
and QoL. Between May 1997 and February 2003, 852 patients were prospectively enrolled 
to receive ADT for 24 weeks. Of these, 554 patients (65%) whose prostate-specific antigen 
(PSA) decreased to <10 ng/ml or at least by 50% (when baseline <20 ng/ml) were 
randomised in a 1:1 manner to either IAD or CAD. In the IAD arm, ADT was withdrawn 
and resumed again for at least 24 weeks whenever PSA increased >20 ng/ml or above the 
baseline level. 
Patients with the most aggressive and the most advanced PC who had a high PSA and 
metastatic disease with more than five skeletal hot spots did not show an adequate 
response to ADT and were not candidates for IAD. IAD was equal with CAD both in 
locally advanced disease (M0) and in metastatic disease (M1) in terms of time to 
progression, to death, to PC-specific death, and to treatment failure. No significant delay in 
the onset of castrate resistance or any improvement in survival was seen with IAD. 
However, QoL was better with IAD than CAD, especially in the domains of activity 
limitation, physical capacity, and sexual functioning. The incidence of adverse events was 
not significantly lower with IAD. Except in the domain of sexual functioning, ADT 
improved QoL to some extent in M1 patients, with IAD conferring some extra benefit. 
IAD is a feasible, efficient, safe and optional method in treatment of locally advanced 
and metastatic PC when compared with CAD. The QoL was better to some extent with 
IAD. In patients with metastatic disease, ADT improved QoL in most domains. 
 
 
 
National Library of Medicine Classification: WB 340, WJ 762, WJ 875 
Medical Subject Headings: Androgen Antagonists/therapeutic use; Drug Administration Schedule; Prognosis; 
Prostatic Neoplasms/drug therapy; Quality of Life; Survival 
 
VI 
 
 
 
VII 
 
 
Salonen, Arto J. 
Jaksoittainen ja jatkuva kastraatiohoito edennyttä eturauhassyöpää sairastavilla potilailla. FinnProstata VII. 
Itä-Suomen yliopisto, terveystieteiden tiedekunta 
Publications of the University of Eastern Finland. Dissertations in Health Sciences 168. 2013. 69 s. 
 
ISBN (print): 978-952-61-1115-5 
ISBN (pdf): 978-952-61-1116-2 
ISSN (print): 1798-5706 
ISSN (pdf): 1798-5714 
ISSN-L: 1798-5706 
 
TIIVISTELMÄ 
 
Androgeenideprivaatio- eli kastraatiohoito (AD-hoito) on ollut 1940-luvulta lähtien 
edenneen eturauhassyövän vakiintunut hoitomuoto. Hoitoon liittyy kuitenkin 
sivuvaikutuksia, jotka vaikuttavat potilaiden elämänlaatuun. Tämän lisäksi hoitovasteen 
kesto on rajallinen, mikä ajan kuluessa johtaa sairauden progressioon eli hoitovasteen 
menettämiseen. 
Satunnaistettu ja kontrolloitu FinnProstata VII -monikeskustutkimus suunniteltiin 
vertaamaan jaksoittaisen AD-hoidon tehokkuutta jatkuvaan AD-hoitoon. Ensisijaisena 
päätetapahtumana oli aika eturauhassyövän progression kehittymiseen. Toissijaisina 
päätetapahtumina olivat kokonais- ja eturauhassyöpäspesifinen kuolleisuus, aika 
tutkimuksen päättymiseen kunkin potilaan kohdalla ja elämänlaadun muutokset. 
Toukokuun 1997 ja helmikuun 2003 välisenä aikana tutkimukseen rekisteröitiin 852 
potilasta. Ne 554 potilasta (65%), joiden eturauhassyöpäspesifinen antigeeni (PSA) laski alle 
arvon 10 µg/l tai vähintään 50%, mikäli alkuvaiheen PSA oli alle 20 µg/l, satunnaistettiin 
suhteessa 1:1 jaksoittaiseen tai jatkuvaan AD-hoitoryhmään. Jaksoittaista hoitoa saaneiden 
hormonihoito aloitettiin uudelleen vähintään 24 viikon ajaksi, mikäli PSA-arvo nousi 
hoitotauon aikana yli lähtötason tai yli arvon 20 µg/l. 
Potilaat, joilla oli huonosti erilaistunut tai laajalle levinnyt eturauhassyöpä (korkea PSA 
ja enemmän kuin viisi luustoetäpesäkettä) eivät reagoineet riittävästi hormonihoitoon 
eivätkä näin soveltuneet jaksoittaiseen kastraatiohoitoon. Jaksoittainen hoito oli teholtaan 
samanveroinen jatkuvaan hoitoon verrattuna progression kehittymisen, kuolleisuuden ja 
tutkimushoidon keston suhteen niin paikallisesti levinneessä (M0) kuin 
etäpesäkkeisessäkin (M1) eturauhassyövässä. Jaksoittainen hoito ei kuitenkaan pidentänyt 
hoitovastetta eikä eloonjäämisaikaa. Elämänlaatu oli parempi aktiivisuuden rajoittumisen, 
fyysisen suorituskyvyn ja seksuaalisten toimintojen osa-alueilla jaksoittaisella hoidolla. 
Haittatapahtumien esiintyvyydessä ei kuitenkaan ollut merkittävää eroa. Kastraatiohoito 
paransi etäpesäkkeistä eturauhassyöpää sairastavien potilaiden elämänlaatua useimmilla 
osa-alueilla paitsi seksuaalisten toimintojen kohdalla. Jaksoittainen annostelu lisäsi AD-
hoidon suotuisaa vaikutusta. 
Jaksoittainen hormonihoito on jatkuvaan hormonihoitoon verrattuna tehokas, 
turvallinen ja vaihtoehtoinen hoitomuoto edenneessä ja etäpesäkkeisessä 
eturauhassyövässä. Jaksoittainen hormonihoito parantaa elämänlaatua tietyin osin. 
Androgeenideprivaatiohoito parantaa etäpesäkkeistä eturauhassyöpää sairastavien 
potilaiden elämänlaatua useimmilla osa-alueilla. 
 
 
Yleinen suomalainen asiasanasto: elämänlaatu; eturauhassyöpä – lääkehoito; kastraatio – jaksotus; 
selviytyminen 
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 1 Introduction   
Prostate cancer (PC) is the most common cause of cancer and the second leading cause of 
cancer death among Finnish males.1 Androgen deprivation therapy (ADT) has been the 
standard treatment for metastatic or advanced PC since the 1940s. However, ADT use is 
associated with acute and long-term adverse effects (AE), which have an impact on the 
patient's quality of life (QoL).  Prostate-specific antigen (PSA) testing and screening during 
the last decades have led to a stage shifting from distant to local-regional stage at the time 
of diagnosis.2 This has led to identification of an increasing number of men with 
asymptomatic locally advanced or locally recurrent PC after curative-intended treatment, 
having life expectancies of years but who carry a risk of significant AEs and declining QoL 
from ADT. Furthermore, the duration of response of PC to ADT is limited, leading to 
disease progression in time.  
These observations have led to the search for alternative treatment strategies and to the 
concept of intermittent androgen deprivation (IAD) or cyclic therapy administered in 
pulses. The two objectives of IAD were to defer hormone resistance for which there was 
some theoretical basis with the potential for prolonging life, and secondly, to improve QoL 
by the intermittent restoration of normal androgen levels and thereby reducing ADT-
related AEs.3, 4 Early trials indicated that IAD could be a promising, feasible, and safe 
treatment modality in the treatment of PC with hormonal therapy. The background to this 
thesis was the attempt to answer three essential questions. Does IAD delay the onset of 
castrate resistance? Can IAD improve the overall survival?5 Does IAD offer better QoL than 
CAD? 
The FinnProstate Study VII (FPVII) was planned in the 1990s as an open-label, 
randomised, controlled, multicenter clinical trial to compare the efficacy of IAD with 
continuous androgen deprivation (CAD) in the treatment of advanced PC in terms of time 
to progression as the primary endpoint. Secondary objectives were overall survival (OS), 
PC-specific survival (PCS), time to treatment failure (TTF), and QoL. The trial was 
registered with ClinicalTrials.gov, identifier NCT00293670. 
2 
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2 Review of the Literature 
2.1 EPIDEMIOLOGY 
Prostate cancer (PC) has been the most common cancer among Finnish males since 1993, 
with 4697 new detected PCs (32% of all new male cancers) in 2010, and the second leading 
cause of cancer death since the middle of the 1980s, with 845 PC deaths (14% of all male 
cancer deaths) in 2010 (Fig. 1).1 Incidence has remained stable during the most recent years 
but mortality has decreased by 3.1% per year since 2000.6, 7 
 
          
 
Figure 1. Number of new cancer cases and age-adjusted mortality trends of common  
sites with prediction among Finnish males (Finnish Cancer Registry).1 
 
   In global terms, PC is the second most common cause of cancer and the sixth leading 
cause of cancer death among men, with almost 899 000 new PC cases and 258 000 PC deaths 
recorded in 2008.6  Incidence rates are among the highest in the United States, although 
they have stabilised during the last 10 years; mortality rates are intermediate, declining by 
4.3% over the last decade.6 In most countries of western and northern Europe, overall 
mortality rates from PC have levelled off since the 1990s, with a peak of 15.0 PC deaths per 
100 000 men in the EU in 1995 but declining to 12.5 per 100 000 in 2006, i.e. a reduction of 
3.8% in recent years.8 
   PSA testing, introduced in the 1980s and early 1990s in many high-income countries, and 
increasing rates of transurethral resection of prostate (TURP) have been shown to increase 
the PC incidence.7, 9-11 PSA testing and screening have led to a stage shifting from the distant 
to the local-regional stage at diagnosis.2 Not only early detection and increased detection 
rates of PC, but also primary treatment changes and advances in therapeutics for recurrent 
and progressive disease, are thought to account for the declining mortality rates.6, 12, 13  
2.2 HISTOLOGY 
Almost all PCs, approximately 95%, are adenocarcinomas.14 Isolated or primary urothelial 
carcinoma represents up to 4% of all prostatic neoplasms.15 The incidence of other primary 
prostate malignancies is much more rare: the proportion of pure squamous cell carcinomas 
is 0.6−1%; sarcomas, originating from nonepithelial mesenchymal components of the 
4 
 
 
prostate, account for less than 0.1%; primary prostatic lymphoma is rare, as well, and much 
less common than secondary infiltration of the prostate.16-18  
   High-grade prostatic intraepithelial neoplasia (HGPIN), referring to architecturally 
benign prostatic acini and ducts lined by atypical cells, is found in 5−8% of needle biopsies; 
a diagnosis of atypical glands suspicious for carcinoma is reported in an average of 5% of 
needle biopsies.19 The average risk of cancer following an atypical diagnosis is 
approximately 40%, whereas the median risk for cancer following the diagnosis of HGPIN 
is 24%.  
   Neuroendocrine (NE) differentiation in prostate carcinoma has been hypothesised to be 
involved in progression to castrate-resistant condition and metastatic disease.20. NE 
differentiation arises in three different forms: carcinoid or carcinoid-like tumor, small cell 
(oat cell) carcinoma, and foci of NE neoplastic cells in prostatic adenocarcinoma. NE tumor 
cells are androgen-insensitive, have a mitogenic effect on adjacent tumor cells (exocrine), 
and are resistant to irradiation or chemotherapy.14 
2.2.1 Gleason scores 
The Gleason score is a standard grading system for PC and has replaced the worldwide 
used World Health Organisation (WHO) differentiation grading system which is 
commonly used to grade other malignancies. The Gleason scoring protocol was published 
in 1966 and was based on the architectural pattern of the tumor, using a 5-point 
differentiation scale. The grade was defined as the sum of the two most common patterns, 
yielding a sum ranging between 2 and 10, with 2 being the least aggressive form and 10 the 
most aggressive.21 The current standard for grading PC is based on the International Society 
of Urologic Pathology (ISUP, UICC) consensus conference held in 2005. According to this 
guideline, the modified Gleason score of PC detected in a prostate biopsy consists of the 
Gleason grade of the most extensive pattern plus the highest grade.22, 23 The Gleason 
grading system is a quintessential prognostic factor of PC.24, 25 In practise, PCs are often 
divided into low-risk (Gleason ≤6), intermediate-risk (Gleason 7) and high-risk cancers 
(Gleason 8−10). 
2.3 STAGING, TNM CLASSIFICATION  
 
The TNM classification of PC is based on the local advancement of the primary tumor, the 
involvement of the regional lymph nodes, and the presence of distant metastasis (Table 1).26, 
27 TNM classification can be used as a prognostic tool in conjunction with the Gleason score 
and PSA. 
 
2.4 DIAGNOSIS  
 
Digital rectal examination (DRE), serum prostate-specific antigen (PSA), and transrectal 
ultrasound (TRUS) -guided biopsies are the main tools in use to detect PC and to undertake 
the PC diagnosis.28 
2.4.1 Digital rectal examination  
DRE was virtually the only tool for early detection of PC before PSA assay. A positive DRE 
has been shown to have positive predictive value in the detection of PC, especially in 
conjunction with increasing PSA.29, 30 In addition, DRE seems to detect more selectively 
high-grade cancers.31, 32  
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Table 1. TNM classification according to Union Internationale Contre le Cancer (UICC). 27 
T - Primary tumor 
TX      Primary tumor can not be assessed 
T0       No evidence of primary tumor 
T1       Clinically inapparent tumor not palpable or visible by imaging  
           T1a    Tumor incidental histological finding in 5% or less of resected tissue  
           T1b    Tumor incidental histological finding in more than 5% of resected tissue  
           T1c    Tumor identified by needle biopsy 
T2      Tumor confined within the prostate 
           T2a    Tumor involves one half of one lobe or less 
           T2b    Tumor involves more than one half of one lobe but not both lobes 
           T2c    Tumor involves both lobes 
T3      Tumor extends through the prostatic capsule 
           T3a    Extracapsular extension (unilateral or bilateral) 
           T3b    Tumor invades seminal vesicle(s) 
T4      Tumor is fixed or invades adjacent structures other than seminal vesicles; external 
           sphincter, rectum levator muscles, and/or pelvic wall 
N – Regional lymph nodes 
NX      Regional lymph nodes not assessed 
N0      No regional lymph node metastasis 
N1      Regional lymph node metastasis 
M – Distant metastasis 
(MX    Distant metastasis not assessed, deleted from the latest version) 
M0     No distant metastasis 
M1     Distant metastasis 
          M1a   Non-regional lymph node(s) 
          M1b   Bone(s) 
          M1c   Other site(s) 
 
2.4.2 Prostate-specific antigen  
PSA, a 33 kilodalton glycoprotein product of the human kallikrein gene family, was 
purified and characterised in 1979.33 PSA has been recognised as an important tumor 
marker for PC since the late 1980s. It is practically organ but not cancer-specific to the 
prostate gland, although PSA and its gene expression have been detected at low 
concentrations in other tissues and also in female serum.34-42 Not only PC, but also other 
conditions, such as benign prostatic hyperplasia, acute or subclinical prostatitis, urinary 
retention, ejaculation, vigorous prostatic massage, prostate needle biopsy, and TURP, may 
elevate the serum levels of PSA.43-50 
   Originally, the standard cut-off of 4 ng/ml was considered as the upper limit of normal 
PSA. Age adjusted PSA reference ranges and the use of percent free-to-total PSA (below 
15% defined as abnormal ratio) have improved PC detection sensitivity in younger men 
and the specificity in older men.42, 51-55 Several modifications of serum PSA value, including 
PSA velocity, PSA doubling time (PSADT), and PSA density, have been described in 
attempts to improve the specificity of PSA in the early detection of PC. However, 
prospective trials have not confirmed the usefulness of these measurements in clinical 
practise.28, 56 
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2.4.3 Transrectal ultrasound (TRUS) and TRUS-guided biopsies 
The TRUS probe was introduced four decades ago by Watanabe et al.57 The clinical 
application of the gray scale TRUS in the search for PC was outlined in the late 1980s.58, 59 
However, TRUS alone is not very accurate in detecting or staging early PC.60-63 Although 
hypoechoic areas on TRUS have been reported to contain cancer more than twice as likely 
as isoechoic areas, a notable proportion of cancers are detected in isoechoic and even in 
hyperechoic sectors of the prostate gland.61, 64, 65 Ellis et al could not detect any differences in 
the pathological staging of hypoechoic and isoechoic cancers but Spajic et al observed 
higher Gleason scores in cancers of hyperechoic areas when compared with isoechoic and 
hypoechoic cancers.65, 66 
   TRUS has been reported to have clinical application in the staging of more advanced PC 
(T3) either by itself or in combination with DRE.67, 68 Three-dimensional TRUS with power 
doppler further improves the accuracy of echographic imaging in the detection and staging 
of local or locally advanced PCs.69-71 TRUS-guided random systematic biopsy protocol has 
been a standard procedure for years to help the surgeon to obtain tissue samples and to 
verify PC diagnosis. In the late 1980s, the systematic sextant biopsy protocol with six 
random ultrasound guided biopsy cores was proposed as a way to increase the accuracy of 
PC diagnosis.72 Later, the extended prostate biopsy scheme consisting of 12 cores has 
become the standard procedure, with increased PC detection rate but without any 
significant increase in adverse events.73 A transperineal approach instead of the transrectal 
counterpart may increase the sensitivity, especially in cases with “gray zone “ PSA (4.1−10.0 
ng/ml) and in transition zone cores.74 
2.4.4 Imaging 
Computed tomography (CT) and magnetic resonance imaging (MRI) can be used to 
evaluate the local extent of PC and the possibility of nodal involvement, although the 
sensitivity and specificity of MRI vary considerably and the sensitivity of CT is low (<30%) 
in local staging of PC. These modalities have low sensitivities in their abilities to detect 
lymph node involvement.75-79  
   The radionuclide bone scan (bone scintigraphy) has been the mainstay for detecting 
skeletal metastases since the 1970s, especially in high-risk PC patients (PSA >20 ng/ml, 
Gleason score >7, tumor stage of T3 or higher, peri-neural tumor invasion), although its 
specificity is limited.80  False positives may occur from degenerative change, inflammation, 
Paget's disease, and trauma. Other imaging modalities such as plain radiography, CT, MRI, 
and positrone emission tomography (PET) can be used in combination with a bone scan in 
attempts to increase sensitivity and specificity.79, 81  
 
2.5 TREATMENT MODALITIES WITH CURATIVE INTENT 
 
Curative treatment aims to remove the cancer with the entire prostate gland or to eradicate 
PC cells from the prostate tissue. There are only a few randomised controlled trials 
comparing the curative-intended treatment modalities with each other. A recent 
comprehensive literature review indicated that a single treatment modality was efficient in 
low-risk (PSA <10 ng/ml, Gleason score ≤6, and cT1c−T2a) and intermediate-risk PC (PSA 
10.1−20 ng/ml, Gleason score 7, or cT2b−c) but a multimodal approach may be needed for 
high-risk PC (PSA >20 ng/ml, Gleason 8−10, or cT3a−4).82 
 
2.5.1 Radical prostatectomy (RP) 
Radical prostatectomy, using a perineal approach, was applied already in the early years of 
the 20th century by Hugh H. Young.83 The first retropubic RP was described in the late 
1940s.84 The standardisation of the anatomic retropubic RP was described by Walsh and 
Donker in 1982.85 Since then, many authors have described applications attempting to 
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improve both cancer-specific (biochemical PSA failure-free, progression-free, and PC-
specific survival) and functional outcomes (urinary continence, erectile function), as well as 
striving to reduce short-term and long-term morbidity.86, 87 Bearing these aims in mind, 
since the late 1990s an increasing number of authors focused their interest on development 
of the technique of laparoscopic RP (LRP).87, 88 A further development of laparoscopic 
technique led to a robot-assisted procedure (RALP) at the beginning of the 2000s.89-92 Both 
LRP and RALP seem to achieve a better perioperative outcome than traditional RP: lower 
blood loss and decreased transfusion rates. The superiority of these treatment modalities 
over traditional RP has not yet been demonstrated in terms of oncological outcomes.93 
However, recent meta-analyses have pointed to better functional outcomes in favor of 
RALP in comparison with traditional RP and LPR.94, 95  
   Scandinavian randomised SPCG-4 trial demonstrated the survival benefit of RP in 
comparison with watchful waiting, with a nearly 40% decrease in the risk of death from PC 
among men <65 years of age.96 RP has been associated with excellent long-term cancer 
control, with the risk of PC death after surgery in modern series between 5 and 10%.86 RP is 
the most common treatment for newly diagnosed clinically localised PC in US.97 Selected 
patients with high-risk PC and with more advanced disease (PSA ≥20 ng/ml, Gleason score 
8−10, tumor stage of T3−4) are also likely to obtain benefits from RP.28, 98-102  
 
2.5.2 External beam radiation therapy (EBRT) 
Three-dimensional conformal radiotherapy (3D-CRT) is the gold standard for delivery of 
EBRT to the prostate gland. Intensity-modulated radiotherapy (IMRT) is an optimised form 
of 3D-CRT to better conform to the shape of the prostate.28, 103 A large meta-analysis of seven 
randomised controlled studies with 2812 patients stated that the biochemical PSA control 
rate (BCR) in a 5-year regression analysis was essentially linear for the total dose of EBRT 
ranging from 64 to 79.2 Gy. Furthermore, between the doses of 70 and 80 Gy, there was a 
significant increase in 5-year BCR of 14, 17.8, and 19.2% in low-, intermediate-, and high-
risk patients.104 A minimum dose of at least 74 Gy is recommended in the EAU guidelines 
for low-risk PC.28 For intermediate- and high-risk PC, an increase of the radiation dose up 
to 80 Gy seems to have a significant impact on 5-year BCR but not necessarily on the overall 
or PC-specific survival (PCS).104-107 On the other hand, the risk for adverse effects increases 
with increasing doses of RT. Gastrointestinal complications and rectal bleeding are the most 
frequently reported side-effects with high-dose EBRT. Similarly, mild acute irritative 
urinary symptoms have been reported but no significant difference in the extent of late-
onset genitourinary toxicity.103, 104, 106, 107  
   New techniques, such as intensity-modulated arc therapy or volumetric-modulated arc 
therapy and the CyberKnife® system, allow real-time tracking of the target and more 
precise EBRT delivery to the prostate. This, in turn, enables doses even higher than 80 Gy 
and better cancer control rates with similar or fewer side-effects than traditional EBRT.108-112 
    Neoadjuvant, concomitant, and adjuvant androgen deprivation therapy (ADT), from a 
few months up to 3 years in length, in combination with EBRT have been reported to 
improve BCR, overall survival (OS), and PCS in intermediate and high-risk PC and in 
locally advanced PC.113-119 
   The post-treatment PSA nadir has been reported to be significantly associated with the 
risk of PC-specific and all cause mortality after RT.120-122 After biochemical PSA recurrence 
post RT, selected patients with confirmed local cancer recurrence and without any evidence 
of metastasis may be candidates for salvage RP, even though the procedure is technically 
demanding and carries high risk of surgical complications.123  
 
2.5.3 Brachytherapy (BT) 
Low-dose rate brachytherapy (LDR-BT) refers to low-energy radioactive sources (iodine-
125 or palladium-103) inserted permanently into the prostate gland which emit radiation at 
a rate of <2 Gy/h. High-dose rate brachytherapy (HDR-BT) uses a high-energy emitting 
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radiation source (iridium-192) with a rate of  ≥12 Gy/h which is implanted temporarily into 
the prostate gland.124, 125 Both approaches are transperineal under TRUS guidance. HDR-BT 
tends to be used for more aggressive or more advanced PC and is usually combined with 
EBRT.125 
   LDR-BT is warranted for use in patients with low-risk PC.28 Good long-term oncological 
and functional outcomes have been reported,126-129 even in patients <60 years of age.130, 131 
However, there is a lack of randomised trials which would have compared BT with other 
treatment modalities.124 Recently, a consensus meeting published guidance on patient 
selection and the optimal technique for focal LDR-BT.132 
 
2.5.4 Focal therapy 
As a result of screening, today there are increasing number of patients with an 
intracapsular small focus of PC, eligible for local treatment, such as cryosurgical ablation 
(i.e. freezing of the prostate), high-intensity focused ultrasound therapy (HIFU), laser-
induced interstitial thermotherapy (LIIT, photothermal ablation), and vascular-targeted 
photodynamic therapy. However, there is a lack of high-quality comparative trials and 
long-term efficacy results.28, 97, 133-135 
 
2.5.5 Active surveillance 
Active surveillance (AS) is an option for immediate treatment intended to be curative. The 
aim is to avoid overtreatment and side-effects from therapy in highly selected patients with 
a life-expectancy of >10 years and with a low-risk PC. The commonly used inclusion criteria 
for AS are PSA ≤10 ng/ml, tumor stage ≤T2a, Gleason score ≤6 (3+3), and PSA density <0.2 
ng/ml per milliliter.136-141 The number of positive biopsy cores and the proportion of 
positivity in a single core are also defined. In some trials, the inclusion criteria have been 
expanded to include patients >70 years of age, PSA ≤15 ng/ml, and Gleason score ≤3+4.139, 142, 
143 The patients are followed up with close surveillance (PSA testing every 3 to 6 months, 
DRE, repeat biopsy at regular intervals) and treated if and when pre-defined thresholds are 
reached (upgrading of Gleason score, increasing proportion of positivity in biopsy cores, 
PSADT <2−4 years).  
   The published data is not yet sufficient to permit drawing any definitive 
recommendations. However, AS seems to produce a very modest decline in PCS among 
men with low-risk PC but does offer a significant benefit in terms of QoL.28, 144-147 The 
recently published results of the PIVOT trial showed no significant difference in all-cause 
and PC-specific mortality during a 12-years of follow-up between RP and observation in 
patients with localised PC and who were randomly assigned to either treatment arm.148 
 
2.6 HORMONAL TREATMENT 
 
The positive effect of androgen deprivation on advanced PC was first described by 
Huggins and Hodges in 1941.149, 150 Subsequently, the standard treatment approach for 
metastatic or advanced PC has been hormonal ablation either by surgical castration or by 
using luteinising hormone-releasing hormone (LHRH) agonists (with or without 
antiandrogens) and, recently, by using LHRH antagonists. Androgen withdrawal results in 
apoptosis, the cellular death of androgen-sensitive PC cells. During apoptosis, a subset of 
cells undergo genetic and biochemical changes leading to fragmentation of the nuclear 
DNA, followed by fragmentation of the cell and the removal of the cellular debris. This 
process results in tumor shrinkage and decreased production of prostate-specific 
proteins.151 In addition to apoptosis, ADT seems to induce characteristics consistent with 
cellular senescence in a subset of androgen-sensitive PC cells.152 Hormonal ablation therapy 
is not curative but simply palliative. 
9 
 
 
2.6.1 Androgen receptor signalling pathways, development of castration resistance 
Testosterone and its metabolite dihydrotestosterone (DHT) are the two major growth 
factors of prostate cells. Testosterone and the other steroid hormones are primarily 
synthesised from cholesterol. Androgens act through the androgen receptor (AR), a steroid-
hormone binding protein, encoded by the AR gene located on the X-chromosome, with 
DHT mainly regulating intraprostatic androgen-mediated processes.153 AR signalling is 
critical to the proliferation and differentiation of epithelial and stromal prostate cells, to the 
development of the normal prostate gland, and it is fundamentally involved in the 
progression from primary PC to metastatic disease.154, 155 After androgens bind to AR, the 
androgen−AR complex dissociates from AR-inactivating proteins (heat shock proteins) in 
the cytoplasm and enters the nucleus, stimulating the transcription of androgen-regulated 
genes which are involved in cell proliferation and PSA production.156, 157 AR coregulators 
are proteins that interact with AR and regulate the AR-signalling pathway either by 
enhancing (coactivators) or by reducing (corepressors) transcriptional activity.158 
   Testosterone synthesis in Leydig cells of testes is regulated by the luteinising hormone 
(LH) released from the pituitary gland which, in turn, is regulated by LHRH from the 
hypothalamus. In prostate cells, testosterone is converted by 5-α-dehydrogenase into DHT, 
the most powerful intraprostatic intracellular androgen (Fig. 2). Prostate cells can produce 
testosterone also from adrenal steroids.153 DHT can also be formed from progesterone by a 
so-called “backdoor pathway”.159 There is evidence that PC cells express all the necessary 
enzymes for, and are capable of, de novo androgen synthesis from available precursors 
instead of blood derived androgens.160-162 It is apparent that prostate cells use the standard 
steroidogenic pathway in the normal androgenic environment, but they develop alternative 
pathways to continue AR-mediated functions in the androgen-deprived environment. 
Thus, PC cell growth becomes independent of the plasma testosterone level after an initial 
response to ADT.153 
 
 
 
 
 
Figure 2. Mechanisms of the androgen action and androgen receptor signalling in prostate 
cells.157 T=testosterone, DHT=dihydrotestosterone, HSP=heat-shock protein, AR=androgen 
receptor, ARE=androgen-responsive element, LH=luteinising hormone, LHRH=luteinising 
hormone-releasing hormone. Reprinted with the permission of the copyright owner. 
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   Although the majority of patients with advanced PC have a good initial response, with up 
to 80−90% responding to ADT, unfortunately, nearly all patients will eventually progress to 
a castration-resistant state. The definition of castration resistant PC (CRPC) includes rising 
levels of PSA, radiographic progression and/or worsening of symptoms even with castrate 
levels of serum testosterone (<50 ng/dl or <1.7 nmol/l).163 The development of CRPC 
involves the activation and re-expression of the AR program following primary ADT.154 
Thus, CRPC continues to be largely dependent on AR and AR-responsive pathways. The 
mean survival time of patients with metastatic disease used to be only 36 months, and the 
median survival time with CRPC used to be approximately 12-18 months before the most 
recent primary treatment changes and advances in treatment for progressive PC.164, 165 
   There are several mechanisms by which PC cells can develop from being androgen-
dependent into a castration resistant state, independent of plasma testosterone 
concentrations (Fig. 3). Amplification of the AR gene and up-regulation or overexpression 
of the AR protein have been detected in CRPC cells.166-168 These changes, as well as 
increased stability of AR proteins, sensitise tumor cells to survive and proliferate even 
under conditions with minimal androgen concentrations.169, 170 AR gene mutations have 
been demonstrated at increasing rates in metastatic or CRPC.171, 172 The mutations in the 
ligand-binding domain lead to decreased ligand specificity, such that the AR may be 
activated also by other steroid hormones, non-steroid hormones, and even by 
antiandrogens.157, 173-175 AR isoforms lacking the ligand-binding domain, called AR splice 
variants, have been identified as being overexpressed in CRPC cells, leading to androgen 
independent cell growth.154, 176 Mutations in coregulator genes or alterations in coregulator 
concentrations may modify the AR activity and promote PC cell growth.153, 157 Furthermore, 
intracellular de novo androgen synthesis can enable CRPC cells to survive despite low 
serum testosterone levels.160, 169 There is evidence for many other cellular and molecular 
mechanisms, called outlaw and bypass pathways, that can activate AR in a ligand-
independent way or can use routes other than androgen−AR pathway to regulate PC 
growth and to circumvent androgen deprivation-induced apoptosis. These include growth 
factors, cytokines, kinases, and other proteins.153, 157 Furthermore, epigenetic alterations and 
miRNA regulation have been speculated to have an impact on the progression of androgen-
independent PC.157 According to clonal selection hypotheses, an androgen insensitive (AI) 
cell population already exists in the benign prostatic epithelium and it is an outgrowth of 
these AI cells which occurs in CRPC under androgen-deprived circumstances.177  
 
 
   
 
Figure 3. Mechanisms of androgen independence in prostate cancers.157 AR=androgen receptor, 
CR=coregulator, T=testosterone. Reprinted with the permission of the copyright owner. 
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2.6.2 Androgen deprivation therapy 
In treatment of PC, the hypothalamic−pituitary−testosterone−AR pathway can be targeted 
at different points, in order to eliminate androgenic action and to try to tackle the 
underlying mechanisms of PC cell proliferation. 
 
2.6.2.1 Surgical castration, LHRH agonists, and LHRH antagonists 
Surgical castration by bilateral orchiectomy eliminates testosterone production from testes, 
causes rapid and sustained suppression of testicular androgens, leading to declines in 
serum testosterone levels to <20 ng/dl (0.7 nmol/l) in most patients.178 LHRH agonists 
(analogues, LHRHa), such as goserelin, leuprorelin, buserelin, and triptorelin, evoke a 
castration effect through negative feedback.179 In fact, continuous stimulation of the 
pituitary by LHRHa induces regulatory changes, possibly down regulation of LHRH 
receptors, receptor desensitisation, and inhibition of LH release.180 The equivalence of 
LHRHas and orchiectomy has been demonstrated, only about 5% of patients treated with 
LHRHas fail to achieve serum testosterone <50 ng/dl (<1.735 nmol/l).181 However, the 
agonistic effect causes an initial stimulation of LHRH receptors with a serum testosterone 
surge during the first week which is associated with clinical flare symptoms in patients 
with advanced disease. The castrate levels of testosterone are achieved in 2−4 weeks.182, 183  
Short-term antiandrogen treatment can ameliorate flare symptoms at the beginning of 
LHRHa treatment.184  
   LHRH antagonists, such as abarelix and degarelix, bind directly to and are competitive 
inhibitors of LHRH receptors, leading to a rapid and reversible reduction in serum 
testosterone levels, without causing any testosterone surge and flare symptoms.185-187 Thus, 
no antiandrogen treatment at the beginning of LHRH antagonist treatment is necessary. 
LHRH antagonists offer a rapid and effective non-surgical castration with symptomatic 
relief in patients with symptomatic metastatic PC.188 
 
2.6.2.2 Androgen receptor antagonists, monotherapy, and maximal androgen blockade 
AR antagonists (antiandrogens, AA) block the intracellular testosterone−AR pathway 
through a competitive inhibition of AR binding with testosterone and DHT. First-
generation AR antagonists are nonsteroidal, such as bicalutamide, flutamide, and 
nilutamide, or steroidal agents, cyproterone acetate. Cyproterone acetate has both an 
androgenic and a progesteronic action, i.e. it binds also to progesterone receptors in the 
pituitary and inhibits the release of LH.189 Bicalutamide can be used as an adjuvant 
treatment after curative-intended treatment with locally advanced disease, as a 
monotherapy in biochemical PSA failure after curative-intended treatment, or as a primary 
treatment in locally advanced disease without metastasis but not in patients with metastatic 
disease.188, 190-192 
   In maximal androgen blockade (MAB), AAs are combined with surgical castration, LHRH 
agonists, or LHRH antagonist. Some trials have shown that MAB can improve oncological 
outcome in metastatic or locally advanced PC,193, 194 some trials have not found success.195, 196 
Two large meta-analyses showed no clear survival benefit with MAB in primary treatment 
of PC when compared with surgical or chemical castration alone.197, 198 AAs can be added to 
castration monotherapy after biochemical PSA relapse to eliminate the stimulating effect of 
small concentrations of adrenal androgens on AR. About one third of patients seem to 
enjoy at least a short-lasting response.199, 200 
   Novel inhibitors of steroidogenesis and androgen synthesis and blockers of the AR-
mediated pathway seem to confer a survival advantage in CRPC. The second-generation 
AR signalling inhibitors, enzalutamide (MDV3100) and RD162, have a high affinity to AR 
without any agonist activity.201, 202 Abiraterone and orteronel (TAK-700) are androgen 
synthesis blockers which inhibit the enzymes needed in steroidogenesis in adrenal glands, 
testes, and prostate.203, 204  
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2.6.2.3 Watchful waiting and deferred therapy 
Watchful waiting refers to delayed symptomatic noncurative treatment in patients who are 
not candidates for a curative-intended aggressive local treatment.28 EORTC 30981 trial 
showed immediate ADT to offer a modest OS benefit but no significant difference in PC-
specific or symptom-free survival in patients without metastasis. The median time to the 
start of deferred ADT was seven years.205 Subsequently, the authors reported that patients 
with a baseline PSA >50 ng/ml and/or PSADT <12 months were at an increased risk to die 
from PC and might obtain benefit from early ADT whereas patients with a baseline PSA 
<50 ng/ml and/or PSADT >12 months were likely to die of causes unrelated to PC. Patients 
with a baseline PSA ≤8 ng/ml had a very low risk of dying from PC within seven years.206 
The tumor grade has a significant impact on survival with low survival rates for poorly 
differentiated PC.207 Watchful waiting is an option for low−intermediate risk localised PC in 
patients >65 years of age and with two or more comorbidities that would increase the risk 
of their deaths from causes other than PC within 10 years.208 
 
2.7 ADVERSE EFFECTS 
 
ADT use is associated with short and long-term adverse effects (AE) which have an impact 
on QoL and may also compromise patient survival. Well-known side-effects of low 
testosterone levels are hot flushes (flashes), sweating during nighttime, erectile dysfunction, 
libido reduction, fatigue, depression, and gynaecomastia. In addition, decreased 
hemoglobin levels, changes in fat and lean body mass, changes in plasma lipoproteins, 
increased insulin levels, osteoporosis, and possibly impaired cognitive functions have been 
reported.209-211 AA monotherapy does not lower testosterone levels and it is associated with 
less side-effects than castration therapy. However, gynaecomastia is more common with 
bicalutamide monotherapy.191, 212 
 
2.7.1 Cardiovascular morbidity 
Several factors which interact with the traditional cardiovascular (CV) risk, such as body fat 
and lean body mass, serum lipoproteins, insulin sensitivity, and obesity, have been 
demonstrated to be associated with ADT.213-217 These have been evaluated to increase the 
odds of serious CV morbidity by as much as 20%, especially during the first 12 months.218 
Many population-based cohort studies have demonstrated the association of ADT with 
increased risk of thromboembolic events, peripheral arterial disease, myocardial infarction, 
and stroke.219-222 Pretreatment CV morbidity seems to further elevate the risk of CV events 
during ADT.223, 224 On the other hand, many reports have shown no evidence of increased 
CV mortality associated with ADT.225, 225-228 Currently, the association between ADT and CV 
mortality remains controversial.211, 229  
 
2.7.2 Osteoporosis and fracture risk 
There is a positive relationship between free testosterone levels and bone mineral density 
(BMD) in elderly men.230 Several studies have demonstrated the association of ADT with 
progressive osteoporosis and with even 5- to 10-fold increased loss of BMD compared with 
healthy controls or men with PC but not on ADT.231, 232 The loss of BMD is progressive in 
conjunction with the duration of ADT but it is most significant during the first years after 
initiation of ADT.232-234 Large population based cohort studies have revealed ADT to be 
associated with an excess risk of fractures or hospitalisation as a consequence of a 
fracture.235-238 However, AA monotherapy does not seem to be associated with an increased 
risk of fractures.238, 239 
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2.7.3 Other adverse effects 
There are conflicting reports on the impact of ADT on cognitive functions (CF), such as 
verbal memory, visuospatial abilities, executive functioning, and language. The trials have 
been relatively small, with reduced power, and CF assessments have vaned from study to 
study. Some trials have demonstrated impaired, other trials have reported improved CFs 
with ADT.240, 241 Finally, one trial demonstrated no effect of ADT on CFs.242  
 
2.7.4 Quality of life 
The adverse effects from ADT impact on QoL. Thus, QoL is an important issue in patients 
receiving ADT. However, QoL should be assessed systematically using validated and 
formulated questionnaires addressing different kinds of functions and domains. One of the 
most commonly used validated questionnaires is The European Organisation for Research 
and Treatment of Cancer (EORTC) QLQ-C30 questionnaire.243 QLQ-C30 incorporates nine 
multi-item scales: five functional scales (physical, role, cognitive, emotional, and social); 
three symptom scales (fatigue, pain, and nausea and vomiting); and a global health and a 
QoL scale. Several single-item (symptom) measures are also included: dyspnoea, sleep 
disturbance, appetite loss, constipation, diarrhoea, and financial impact.   
   In 1995, Cleary et al devised a formulated and validated 30-item questionnaire for 
multinational use to explore the value of ADT for advanced PC.244 The questionnaire 
consisted of ten domains: pain (four items), social functioning (two items), emotional well-
being (five items), vitality (three items), activity limitation ( one item), bed disability (one 
item), overall health (one item), physical capacity (six items), sexual functioning (four 
items), and sexuality (three items).  
   The interpretation of the significance of changes in QoL scores is challenging. Small 
numerical differences in mean scores derived from QoL assessment instruments may 
provide statistically significant results when large sample of subjects are involved, but the 
clinical significance of such small numerical differences is far from clear. To signify the 
importance of a change, Osoba et al (1998) devised the term “subjective significance” when 
referring to the changes in QoL scores that the subjects themselves considered to be 
important.245 They developed a subjective significance questionnaire (SSQ) to determine the 
numerical changes in the QLQ-C30 scores that were present when the subjects indicated a 
change on the SSQ: no change; a slight change, worse or better; moderate change; very 
great change. In addition, evidence-based guidelines have been published for the 
determination of sample sizes in clinical trials and for interpretation of differences in QLQ-
C30 scores.246  
 
2.7.5 Testosterone recovery 
Testosterone recovery is considered essential for relief from ADT-induced AEs and for 
achieving an improvement in QoL when concerning IAD.164 The testosterone recovery rate 
has been demonstrated to be dependent on the baseline pretreatment testosterone prior to 
ADT, the duration of ADT, and on the age of patient.247-250 In theory, time off therapy should 
be long enough to permit recovery of testosterone which is necessary for testosterone-
induced tumour cell differentiation to defer hormone resistance, reduced side effects, 
recovery of sexual function, and normal sense of well-being.164 
   Early studies regarding IAD indicated that testosterone level normalisation occurred 
within 2 to 6 months.4, 251-257 However, Irani et al showed that a predetermined off-treatment 
period (TOFF) of 6 months was not long enough to regain normal testosterone values or to 
achieve any difference in QoL between IAD and CAD after receiving six months in one 
year of MAB intermittently.258 Another trial demonstrated that a median time of seven 
months was needed for normalisation of testosterone after withdrawal of ADT.247 
   In phase III trials, the proportion of patients showing normalisation of serum testosterone 
during TOFFs varied from 35 to 93%, and the time to serum testosterone normalisation 
ranged from 100 days up to 12 months. The percentage of patients experiencing 
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testosterone recovery and the levels of serum testosterone reached during TOFFs decreased 
in consecutive cycles.250, 259-261 It has to be stated that not all phase III trials have reported 
testosterone recovery rates. 
 
2.8 INTERMITTENT ANDROGEN DEPRIVATION 
 
PSA testing and screening have resulted in an earlier diagnosis of PC, i.e. patients of 
younger ages and at earlier stages of disease.2 This, in turn, has led to increasing number of 
men with asymptomatic locally advanced or locally recurrent PC, who by virtue of the 
natural history of the disease have life expectancies of years and are at risk of experiencing 
significant AEs and declining QoL from ADT. Therefore, the clinicians have to try to 
balance the potential benefits of early ADT with the risks of long-term complications from 
ADT.164 Furthermore, hormonal ablation therapy is not curative but simply palliative with a 
limited time of response.  
   These observations triggered the search for alternative treatment strategies in the 1980s 
and 1990s to optimise the effectiveness of ADT while minimising AEs. The widespread use 
of potentially reversible medical castration and the possibility of monitoring the course of 
PC via the PSA assay led to the concept and development of intermittent androgen 
deprivation (IAD) or cyclic therapy, a form of ablative therapy administered in pulses.  
   Bruchovsky et al (1990) indicated that the development of androgen-independent cells 
within the Shionogi carcinoma was greatly increased in an androgen-depleted 
environment. This appeared to be linked to cessation of androgen-induced differentiation 
of tumorigenic stem cells and may have been a result from the ability of small number of 
initially androgen-dependent stem cells to adapt to the altered hormonal environment.262 
The rationale behind IAD was based on the hypothesis that if tumor cells surviving 
androgen withdrawal were forced along a normal pathway of differentiation by androgen 
replacement, then apoptotic potential might be restored and in that way progression to 
androgen independence delayed. Thus, it should be possible to maintain the apoptotic 
potential and to defer hormone resistance by achieving repeated cycles of androgen-
stimulated growth, differentiation and androgen-withdrawal regression of tumor.164, 255 The 
objectives of IAD were, at least on a theoretical basis, to defer hormone resistance with the 
potential for prolonging the life, and, secondly, to improve the QoL by the intermittent 
restoration of normal androgen levels and reducing AEs related to ADT.3, 4 
 
2.8.1 Animal studies 
The concept of treating cancer with intermittent endocrine therapy derives from studies by 
Noble (1977) regarding tumor biology in hormone-dependent tumors in various organs of 
the Nb strain of rats.263 The first studies in animal models were conducted to determine 
whether intermittent hormonal therapy could delay the onset of hormone-independent 
growth of cancer. Several different methods were used but the results were conflicting. 
Russo et al (1987) determined the effect of intermittent diethylstilbestrol diphosphate (DES) 
on the Dunning R3327 rat PC and Trachtenberg (1987) examined the effect of intermittent 
testosterone implants on the Dunning R3327 PC in castrated male rats. No survival or any 
growth-retarding advantages were demonstrated with IAD when compared to castration or 
continuous androgen deprivation (CAD). Both studies indicated that IAD was clearly 
inferior to CAD in this respect.264, 265 However, it was speculated later that the Dunning 
R3327 tumor model was androgen-sensitive but not androgen-dependent, which could 
have explained the results.5, 164, 266  
   In other studies either the androgen-dependent Shionogi carcinoma was transplanted into 
a succession of male mice prior to castration267 or castrated mice bearing LNCaP tumours 
were intermittently subjected to hormonal stimulation via testosterone implants.268, 269 
Akakura et al (1993) demonstrated that IAD could induce multiple apoptotic regressions of 
the Shionogi tumor.267 Furthermore, Buhler et al (2000) could not detect any significant 
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difference in survival between these two treatment models and proposed that IAD was not 
associated with any decrease in survival.268 Gleave et al (1996) reported that IAD could 
prolong the time to androgen-independent PSA production by 3-fold with serum PSA 
levels increasing 9-fold faster with CAD.270  
 
2.8.2 Pilot studies and phase II trials 
The first clinical studies were performed to assess the feasibility of IAD in the treatment of 
PC. The concept of IAD for PC was first clinically examined by Klotz et al (1986) who 
reported results of intermittent DES therapy in 19 patients with advanced PC and of 
intermittent flutamide in one patient with the overall conclusion that IAD was not harmful 
to the patients. The authors reported recovery of potency after discontinuation of therapy 
during the period off treatment (TOFF), thus suggesting a beneficial effect on patient-rated 
QoL.271 The early clinical studies were rather heterogeneous in terms of the patient 
population (metastatic disease, localised disease or biochemical failure after definitive local 
therapy) and the proposed treatment guidelines. For example, the methods and length of 
the initial ADT and the criteria for withdrawal and resumption of ADT varied from study 
to study.3, 4, 249, 251-257, 266, 272-284 In most trials, the PSA cut-off level was 4 ng/ml for withdrawal 
of ADT and 10 to 20 ng/ml for resumption of ADT, this being guided mainly by the 
importance of tumor burden. The duration of the treatment-on phase (TON) ranged from 3 
to 12 months but was usually 6 to 9 months before withdrawal of ADT. Mean and median 
duration of TOFFs showed a tendency with time to decrease from cycle to cycle. Median 
times to progression varied extensively according to advancement of PC. 
   A few studies have reported a median follow-up for more than five years, demonstrating 
the feasibility of IAD in long-term treatment of PC.282-286 Prapotnich et al (2009) reported 
their 16-year clinical experience with a median follow-up of 81 months and with one 
patient even reaching his 13th cycle. Cycle duration decreased progressively from 23.7 
months in the first cycle to 10.1 months in the 12th one, with a mean of 14 months off 
therapy. It seemed that patient's age, Gleason score, and initial PSA level were significant 
prognostic factors.286 Furthermore, the PSA nadir during the first TON and the duration of 
the first TOFF have been proposed to be predictors of the time to clinical progression and 
CRPC.287-289  
   QoL was not assessed systematically via questionnaires in many of the early 
nonrandomised trials. In spite of the lack of any formulated questionnaire, many of these 
trials not only highlighted the feasibility of IAD but described an improvement of QoL 
during TOFF.251, 252, 274, 279 However, some of the phase II trials did utilise some kind of 
questionnaire to assess QoL.249, 255, 256, 266, 277, 284 Most of these have revealed an improvement of 
QoL, at least to some extent, during TOFF. In order to evaluate QoL, Albrect et al (2003) 
designed a 14-item ad-hoc questionnaire addressing symptoms and level of pain, overall 
QoL and the inconvience related to monthly blood tests. Overall QoL seemed to be slightly 
better during TOFF, but no definitive conlusions could be drawn. The proportion of potent 
men at the entry was only 17.8%, and thus, potency preservation seemed to be of minor 
importance.266 Sato et al (2004) assessed QoL by a self-administered FACT-G questionnaire 
and by the IIEF-5-questionnaire. There seemed to be a remarkable and significant 
improvement of QoL in the categories of potency and social/family well-being during 
TOFF. Testosterone levels recovered to the normal range in 87% of patients within a 
median of 13 weeks. They detected an association between testosterone recovery and 
improvements in QoL scores and concluded that IAD offered major advantages over CAD 
with respect to QoL.255 Bruchovsky et al (2008) assessed QoL using Southwest Oncology 
Group 9346 QoL questionnaire and the American Urological Association (AUA) symptom 
scores questionnaire. QoL improved in several categories of physiologic and psychologic 
function when ADT was stopped.284 
   The QLQ-C30 questionnaire was used in some of the early pilot and phase II trials. 
Bouchot et al (2000) could not observe any modifications in social activities, occupational 
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activities, emotional status, and sexual functions between pre-treatment, on-treatment, and 
off-treatment periods. Only the direct hormonal side-effect of hot flushes was reported to 
be improved during TOFF.277 Cury et al (2006) reported IAD to limit hormone-related AEs 
but, generally, no significant change of QoL between off-treatment and on-treatment 
periods.256 Spry et al (2006) demonstrated a trend for a progressive improvement of QoL 
that paralleled the testosterone recovery. The improvement reached its maximum by 
months 9−12; recovery was slower than the rate of deterioration of QoL during TON which 
lasted nine months.249 
 
2.8.3 Phase III trials 
The first randomised study comparing IAD with CAD was reported by de Leval et al in 
2002.290 Since then, a few more randomised trials with locally advanced, metastatic or 
recurrent PC have been published (Table 2). In most of the trials, the treatment regimen has 
consisted of MAB. The duration of the initial treatment-on phase has varied between three 
and eight months, but commonly was six months. The PSA cut-off level was usually 4 
ng/ml for withdrawal of ADT and 10 to 20 ng/ml for resumption of ADT, as in the phase II 
trials. The PSA nadir during the first TON and the duration of the first TOFF have been 
demonstrated to be predictors of the time to clinical progression and to death.259, 291, 292 
   The SEUG trial 9401 used MAB for only 3 months before randomisation, without any 
demonstrated impact on survival. Gleason score and metastatic status were predictors of 
PSA response at randomisation, metastatic status and PSA level at randomisation (<2 vs 2−4 
vs >4 ng/ml) were predictors of progression and PC death. No difference in OS between 
treatment arms was demonstrable (p=0.84), but a slightly higher risk for progression and 
cancer death emerged in the IAD arm. Of the IAD patients, 50% were off therapy for at least 
52 weeks following randomisation, and 29% off therapy for >36 months.292 
   De Leval et al reported a mean delay of seven months to androgen-independence with 
IAD when compared with CAD. Progression rates were significantly lower with IAD than 
with CAD in patients without bone metastasis (p<0.001) and in patients with a high Gleason 
score >6 (p=0.018). No significant difference in progression rates was observed in patients 
with bone metastasis (p=0.32) or with Gleason score ≤6 (p=0.082). In the IAD arm, mean 
percentages of time off therapy ranged from 52.1% to 61.0% across eight successive cycles. 
The average duration of TOFF decreased almost linearly by approximately 20 days or 0.9% 
with each additional completed cycle.290  
   Langenhuijsen et al evaluated maximal androgen blockade given intermittently or 
continuously in 173 patients with metastatic (N+M0 or M1) PC. High baseline PSA (<50 vs 
≥50 to <500 vs ≥500 ng/ml), pain, and high PSA nadir (≤0.2 vs >0.2 to ≤4 vs >4 ng/ml) were 
strong predictors for progression with ADT. Overall, patients on IAD showed a trend 
towards higher progression rates and seemed to fare worse than those receiving CAD, 
especially in patients with PSA nadir ≤0.2 ng/ml (2-year risk of progression 53% vs 31%, 
p=0.03). In the IAD arm, the mean duration of the 1st TOFF was 19 months, with the 
percentage time off-therapy decreasing with successive cycles.259 Mottet et al reported no 
significant differences in PFS or OS among 173 patients with M1 disease randomised to 
IAD or CAD. The number and percentage of days off-therapy decreased from a mean of 
126 days (54.6%) in the 1st cycle to 85 days (49.2%) in the 7th cycle.293 
    Recently published data of the large trial (JPR7) comparing IAD and CAD among 
patients with recurrent PC after definitive radiotherapy revealed no significant difference 
in OS between the treatment arms (8.8 vs 9.1 years in IAD vs CAD).250 However, a few more 
PC deaths were reported in the IAD than CAD arm, with 7-year cumulative disease-related 
death rates of 18% and 15% (p=0.24). The median duration of TOFFs decreased 
progressively, with 20.1 months in the 1st, 13.2 months in the 2nd, and 9.1 months in the 3rd 
cycle, and it declined to approximately 4 to 5 months in subsequent cycles. 
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   The most recent results of the vast S9346 (INT-0162) trial with 3040 enrolled and 1535 
randomised patients with metastatic PC showed a median survival of 5.1 and 5.8 years 
years for IAD and CAD, with a 10% relative increase in the risk of death with IAD (HR 1.10, 
90% CI 0.95−1.23).294 IAD was inferior to CAD in patients with minimally extensive disease 
(5.4 vs 6.9 years; HR 1.19, 95% CI 0.98−1.43) but not in those with extensive disease (4.9 vs 
4.4 years; HR 1.02, 95% CI 0.85−1.22). PSA nadir (≤0.2 vs >0.2 to ≤4 vs >4 ng/ml) was a strong 
predictor for risk of death. Higher PSA, Gleason score ≥8, worse performance status 
(SWOG 0−1 vs 2−3), younger age, and presence of bone pain were independent predictors 
for failure to achieve PSA ≤4 ng/ml after seven months of ADT.291  
   Most of the phase 3 trials have used a validated questionnaire to evaluate QoL changes. 
Three of these trials could detect no clinically relevant difference in QoL between IAD and 
CAD but less side-effects were reported with IAD.250, 259, 293, 294 Verhagen et al reported better 
physical and emotional functions but worse cognitive functions with IAD than CAD 
(p<0.05).295 In the SEUG trial 9401, side-effects of hot flushes, gynaecomastia, headaches, 
and skin complaints were more frequent in the CAD arm. Surprisingly, QoL was reported 
to be slightly lower with IAD in the other domains, except sexual quality.292 Hussain et al 
found better erectile function and mental health with IAD when compared with CAD at 
month three but not thereafter. 294 
   Testosterone recovery rates have been reported in many but not all of the phase III trials. 
The data from the TULP study revealed that the median testosterone level started to rise 
above 0.2 ng/ml at 10 months and it was restored to normal levels at 12 months after 
cessation of the induction ADT (6 months) in the IAD arm. A median of four months was 
needed for testosterone to rise above the castrate level, with 92% of patients having a 
normalised serum testosterone at the end of the 1st cycle and 54% at the end of the 2nd 
cycle.259 In the JPR 7 trial, only 35% of patients experienced a return to pretreatment levels 
of serum testosterone during the first TOFF.250 Calais da Silva et al reported significantly 
higher geometric mean testosterone at fixed points at 3-monthly-intervals in the subgroup 
of IAD (192 patients at entry) compared with CAD (178 patients).292 In the trial of Mottet et 
al, testosterone was found to increase to a mean value of 4.83 ng/ml during 1st TOFF within 
three months after cessation of ADT compared with the mean level of 0.29 ng/ml during 1st 
TON.293 Tunn et al (2012) reported testosterone normalisation in 79.3% and 64.9% of 
patients during the 1st and 2nd TOFF, with a median time of 100 and 115 days to 
normalisation.260 Previously, Tunn et al (2004) reported testosterone normalisation rates of 
93% and 79.4% during the 1st and 2nd TOFF, with mean durations of TOFFs of 10.32, 5.97, 
and 3.60 months in the 1st, 2nd, and 3rd cycle, respectively.261 
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3 Aims of the Study 
Androgen deprivation therapy (ADT) has been the standard treatment for advanced PC for 
seven decades. Despite an initial response rate of up to 80−90%, many patients experience a 
relapse within a few years. Furthermore, many patients are likely to experience significant 
AEs with a deterioration of QoL from ADT. These observations triggered the search for 
alternative treatment strategies, such as intermittent dosing, to optimise ADT efficacy while 
minimising AEs. 
The general aim of this study was to compare intermittent and continuous androgen 
deprivation in patients with locally advanced or metastatic PC in terms of time to 
progression, to death, to PC-specific death, and to treatment failure, and to compare the 
effect of these treatment modalities on the quality of life. When the FPVII trial was planned 
in the middle of the 1990s, there were no published randomised, controlled trials regarding 
IAD. 
 
The specific aims of the study were: 
 
1. To identify what kinds of patients with advanced PC are appropriate for IAD. 
 
2. To compare IAD and CAD on progression-free survival (PFS), overall survival (OS), 
PC-specific survival (PCS), and treatment failure survival (TFS). 
 
3. To compare the effects of IAD and CAD on the quality of life (QoL) and on the 
prevalence of adverse effects from ADT. 
 
4. To compare the effect of IAD and CAD on PFS, OS, PCS, TFS, and QoL separately in 
the subgroups of patients with nonmetastatic (M0) and metastatic (M1) disease. 
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4 Patients and Study Design 
4.1 PATIENTS 
4.1.1 Inclusion criteria 
The FinnProstate Study VII (FPVII) was conducted as an open-label, randomised, 
controlled, parallel-group, multicenter clinical trial in 27 clinics in Finland between May 
1997 and January 2010 (appendix 1). The trial was designed to compare IAD and CAD in 
patients with histologically confirmed metastatic PC (M1) at any PSA level. In an attempt to 
increase recruitment, the inclusion criteria were widened in June 1998 to include patients 
with locally advanced or recurrent PC without metastases (M0). M1 patients at any PSA 
level, M0 patients at PSA level ≥60 ng/ml, or T3−4M0 PC at PSA level ≥20 ng/ml, or 
previously surgically or radiotherapy-treated local PC and PSA recurrence ≥20 ng/ml; no 
previous hormonal or medical treatment for PC; and performance status WHO 0−2 with a 
life expectancy of at least 12 months, represented the inclusion criteria. The trial protocol 
and amendments were approved by Ethics committees in each center. All patients gave a 
signed informed consent.  
 
4.1.2 Hormone sensitivity of the prostate cancer 
In order to establish hormone sensitivity of PC, all patients recruited received LHRHa 
treatment goserelin depot 3.6 mg (Zoladex®, AstraZeneca) subcutaneously every 28 days 
for 24 weeks (run-in period). The antiandrogen (AA), cyproterone acetate (CPA), was 
administered 100 mg bid during the first 12.5 days in order to minimise the flare reaction. 
The hormone sensitivity was defined as a PSA decrease to <10 ng/ml or by at least 50% in 
patients with the baseline value <20 ng/ml. 
 
4.1.3 Exclusion criteria 
The exclusion criteria for the run-in period were as follows: any previous hormonal or 
medical treatment of PC; previous history or presence of any malignancy other than basal 
or squamous cell carcinoma of the skin within the last 5 years; any medication or treatment 
affecting sex hormone status; patient receiving any other investigational drug within 3 
months prior to entering the trial; any physical or mental condition which could interfere 
with the patient's ability to comply with scheduled visits. 
 
4.2 STUDY DESIGN 
 
4.2.1 Visit 1 and 2 
At visit 1, the eligibility of the patient was checked. The patient's demographic details (age, 
sex, race, weight, height), previous significant medical history and concomitant medication 
usage were recorded. A physical examination was performed at each visit. Any 
abnormalities, which may have been related to trial drugs but were not related to PC, were 
recorded. Any worsening of patient's physical condition compared with baseline, which 
may have been related to trial drugs, was reported on the suspected adverse drug reaction 
(ADR) form. An isotopic bone scan or a skeletal x-ray or both assessments were performed 
at visit 1 for every patient, at visit 3 for patients with bone metastases (M1), and thereafter 
when clinically indicated. Any other clinically measurable non-skeletal metastases were 
assessed by clinical examination at each visit, except at visit 2.  Chest-x-ray was performed 
at visit 1 and thereafter when clinically indicated. Ultrasound, X-ray, CT-scan etc. were 
optional. DRE was done at each visit, except visit 2, for assessment of prostate dimensions 
(two largest diameters). TRUS was an optional method. Laboratory tests for testosterone, 
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alkaline phosphatase (ALP), creatinine (crea), blood count (haemoglobin, haematocrit, total 
white blood cells, erythrocytes, MCV, MCH, MCHC), as well as urinalysis (pH, proteins, 
glucose, ketone bodies and sediment), were measured at each visit except at visit 2. PSA 
was measured at each scheduled visit every 12 weeks and more frequently during TOFF in 
the IAD arm when necessary.  
   The aim of visit 2 was to evaluate the safety and efficacy of LHRHa treatment and to 
check the patient's initial response to the trial treatment. The visit included PSA assay, 
physical examination, and assessment for any ADR or any changes in concomitant 
medication usage.   
 
4.2.2 Randomisation (visit 3) and follow-up visits 
Patients who fulfilled all inclusion criteria, who completed the 24-week run-in period, and 
whose PC showed hormone sensitivity, were randomised at visit 3. In order to meet the 
randomisation criteria, PSA level had to decrease to <10 ng/ml or by at least 50% if the 
baseline value was <20 ng/ml. Patients with a hormone sensitive PC who were eligible for 
randomisation were allocated in a 1:1 manner to IAD or CAD by using the rand-function of 
Excel program. Patients not eligible (Group A) and patients eligible for randomisation 
(Group B) were evaluated in the interim analysis for prognostic markers affecting the initial 
response to ADT. 
   In the CAD arm, patients continued with goserelin depot 3.6 mg every 28 days or 10.8 mg 
every 12 weeks or they underwent bilateral orchiectomy. In the IAD arm, LHRHa was 
withheld immediately after randomisation and resumed, including flare protection with 
CPA, for at least 24 weeks whenever PSA increased above 20.0 ng/ml or above the baseline 
value, and withheld again by the same criteria as for randomisation. LHRHa was continued 
if PSA did not decrease to <10.0 ng/ml or decreased by <50% of the baseline. Patients in the 
IAD arm and patients with metastases were examined every 12 weeks. Patients in the CAD 
arm and without any metastases were monitored every 24 weeks, but laboratory tests were 
assayed at 12-weekly intervals (Fig. 4). From the randomisation forwards, the treatment 
cycle (duration in weeks) was defined as time off treatment (TOFF) plus time on treatment 
(TON). 
4.2.3 Treatment failure, progression, and death 
Treatment failure (TF) was defined as withdrawal from the protocol for any reason. Criteria 
for TF and disease progression are listed in table 3. Any progression criterion encountered 
during TOFF was considered as a real progression if initiation of ADT failed to relieve the 
symptoms. After withdrawal, patients were treated according to the investigator's decision 
(e.g. MAB, chemotherapy etc.). Patients were followed up every 12 weeks until progression, 
thereafter, every 24 weeks until death. Time to treatment failure (TTF), progression, and 
death were calculated from the date of randomisation. 
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       PATIENT ELIGIBILITY ASSESSED/CONSENT OBTAINED    
 
 
   
 
 
 LHRHa FOR 24 WEEKS + CPA FOR 12.5  DAYS  (RUN-IN-PERIOD) 
 
 
 
RESPONSE TO LHRHa NO RESPONSE TO LHRHa  =>  EXCLUDED  
       
   
 
                         RANDOMISATION                    
   
 
 
    INTERMITTENT       OR      CONTINUOUS ANDROGEN DEPRIVATION 
             => LHRHa continues or orchiectomy 
 
 
    LHRHa WITHHELD 
 
                   PSA rise 
 
    LHRHa RESUMED (for at least 24 weeks + CPA for 12.5 days) 
 
 
                 PSA decrease                  PSA unchanged                evidence of progression  
 
    LHRHa WITHHELD   LHRHa CONTINUES           WITHDRAWN 
 
 
FOLLOW-UP EVERY 12 WEEKS UNTIL PROGRESSION.  
THEREAFTER, SURVIVAL STATUS  EVERY 24 WEEKS. 
 
Figure 4. Trial plan. LHRHa=Luteinising hormone-releasing hormone analogue; 
CPA=Antiandrogen cyproterone acetate; PSA=Prostate-specific antigen 
 
 
Table 3. Criteria for treatment failure and progression. 
 
Treatment 
failure 
 
death; adverse drug reaction requiring cessation of the randomised treatment; cancer 
progression; patient unwilling or unable to continue according to the protocol; patient 
refused the randomised treatment; administration of any additional systemic therapy or 
radiotherapy for prostate cancer; patient lost to follow-up; investigator’s decision that it 
was in the patient’s  best interest to stop the randomised therapy 
 
 
Progression  
 
appearance of any new or worsening of existing bone metastases; increase in dimensions 
(by 25% or more) of any existing  or appearance of any new extraskeletal metastases; 
ureteric obstruction either by primary tumour or pelvic nodal disease; lymphoedema of 
lower extremities due to pelvic nodal involvement; recurrent vesical obstruction, bleeding 
(macroscopic hematuria) or pain due to growth of primary tumor; PSA >100 ng/ml or PSA 
progressively elevated in two successive 12 weekly measurements during endocrine 
treatment (PSA should be >20 ng/ml for patients with baseline PSA ≥20 ng/ml, or PSA 
>visit 1 value with baseline PSA <20 ng/ml); death before evidence of objective 
progression 
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4.2.4 Quality of life analysis 
QoL was monitored at each visit except at visit 2 by a formulated, validated, and self-
administered 30-item Cleary questionnaire addressing ten domains: pain (questions 1−4), 
social functioning (5−6), emotional well-being (7−11), vitality (12−14), activity limitation 
(15), bed disability (16), overall health (17), physical capacity (18−23), sexual functioning 
(24−27), and sexuality (28−30) (appendix 2 and 3).244 Patients continued to the last domain if 
they answered “yes” to the question 27. The sum of the numerical values of answers in each 
domain was recorded. In the statistical analysis, answers for questions 8, 10, 13, and 27 
were renumbered in reverse. In summary, lower scores indicated better health in the 
domains of pain, activity limitation, bed disability, physical capacity, and sexuality. Higher 
scores indicated a favourable outcome in the domains of social functioning, emotional well-
being, vitality, overall health, and sexual functioning. 
 
4.2.5 PSPA-score 
In addition to the QoL questionnaire, patient well-being was assessed by the PSPA-score, 
which represents the sum of the WHO performance status score, cancer-related pain score, 
and analgesics use score (appendix 4). PSPA and QoL questionnaire scores, PSA, and serum 
testosterone were analysed and summarised at the end of each TOFF and TON in the IAD 
arm and at approximately the same time point in the CAD arm. The approximate time 
point was defined by calculating the mean durations of previous cycles and the mean 
duration of the present TOFF or cycle. Patients in the CAD arm were selected by taking into 
account the visit closest to this point. 
 
4.2.6 Adverse drug reactions (ADR), adverse events (AEV), and serious adverse events 
(SAE) 
Any ADR, AEV, or SAE were inquired about at each visit, monitored, and summarised by 
the COSTART preferred term (PT; e.g. fracture) and primary body system (system of organ 
classes, SOC), according to the Medical Dictionary for Regulatory Activities (MedDRA).296 
The following SOCs were included: cardiac; vascular; metabolism and nutrition; 
musculoskeletal and connective tissue disorders; injury, poisoning, and procedural 
complications. A description of any event, the intensity, duration, any action, and outcome 
were recorded, and the relationship to the trial treatment were evaluated. Any ADR was 
also inquired 28 days after cessation of the trial treatment (treatment failure) or after 84 
days for patients in the CAD arm with 10.8 mg depot.   
 
4.2.7 Statistical analysis 
The study was originally designed to enrol patients with metastatic PC. In conjunction with 
the widened inclusion criteria and with this more heterogeneous patient population, fewer 
events were expected to occur in the follow-up time previously specified as 36 months. 
Thus, the primary analysis was meant to be completed 14 months later, specified as 50 
months. Median time to progression (primary objective) was estimated as 20.5 months, 
with a total of 600 patients (300:300) required to detect a hazard ratio of 1.345 with 90% 
power for CAD vs IAD. In comparing the patient characteristics between the treatment 
arms, Student`s t-test, the median test or chi-square ( 2) test were used. PFS, OS, PCS, and 
TFS were analysed using a univariate unadjusted Cox model; these were graphically 
displayed by the Kaplan-Meier method. Hazard ratios were estimated together with the 
associated 95% confidence interval and p-value. Differences in means of the QoL 
questionnaire were assessed by the Mann-Whitney U-test (MWU), the 0.5 standard 
deviation (SD) rule,297 and repeated measures analysis of variance. PSPA-scores were 
analysed by using summary statistics only, differences in prevalences of ADRs and (S)AEs 
by the Chi-square test ( 2). All statistical tests were two-sided at a 5% significance level.  
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5 Results 
Between May 1997 and February 2003, 852 patients were prospectively enrolled in 27 clinics 
to receive ADT. After the run-in period, 298 (35%) failed to meet the randomisation criteria 
and were excluded (group A). Of these, 259 (87%) did not meet the randomisation criteria, 
showed disease progression, or died. The remaining 554 subjects (65%) were randomised 
(group B): 274 (49.5%) to the IAD and 280 (50.5%) to the CAD arm. No patient with 
recurrent PC after prostatectomy or radiotherapy was enrolled. 
5.1 COMPARISON BETWEEN PATIENTS ELIGIBLE AND NOT ELIGIBLE 
FOR RANDOMISATION 
 
The characteristics of the non-randomised (group A) and randomised patients (group B) are 
presented in table 4.  
 
Table 4. Patient characteristics at entry in non-randomised (A) and randomised (B) patient 
groups. 
  Non-randomised 
(group A) 
n=298, (35%) 
 
Randomised 
(group B) 
n=554, (65%) 
Total 
n=852, 
(100%) 
p 
Age Mean (range) 
Median 
 
69.9 (46-90) 
70 
71.5 (47-94) 
72 
70.9 (46-94) 
71 0.007** 
T-category T1-2 
T3 
T4 
 
23 (8%) 
162 (54) 
113 (38) 
67 (12) 
354 (64) 
133 (24) 
90 (10) 
516 (61) 
246 (29) 
<0.001* 
 
M-Category M0 
M1 
 
55 (18) 
243 (82) 
277 (50) 
277 (50) 
332 (39) 
520 (61) 
<0.001* 
 
 
Hot spots ≤5 
Hot spots >5 
 
67 (28) 
176 (72) 
163 (59) 
114 (41) 
 
<0.001* 
 
WHO grade 
 
I 
II 
III 
X 
 
21 (7) 
159 (53) 
117 (39) 
1 (<1) 
75 (14) 
339 (61) 
140 (25) 
0 (0) 
96 (11) 
498 (58) 
257 (30) 
1 (<1) 
<0.001* 
 
PSA (ng/ml) 
 
Mean (range)  
Median 
(n) 
 
820.0 (0.9-12000.0) 
261.3 
(297) 
151.5 (4.4-5123.0) 
67.6 
(554) 
 
<0.001** 
 
ALP (IU/l) 
 
Mean (range)  
Median 
(n) 
 
812 (72-9518) 
303 
(291) 
277 (73-4341) 
173 
(545) 
 
<0.001** 
 
Testosterone 
(nmol/l) 
 
Mean (range)  
Median 
(n) 
14.1 (1.0-38.7) 
13.5 
(279) 
15.1 (0.7-41.7) 
14.5 
(528) 
 
 
0.033** 
 
* 2-test ; **t-test; T=tumour stage (local advancement); M=metastatic status; WHO=World 
Health Organisation; PSA=prostate-specific antigen; ALP=alkaline phosphatase. 
 
The mean and median age of the enrolled patients was 71 years (range from 46 to 94 years), 
with 60% of patients 70 years or older. PSA ranged between 0.9 and 12000 ng/ml at entry. 
Only 4% of patients had PSA <20.0 ng/ml, 31% between 20.0−60.0 ng/ml, and 65% >60.0 
ng/ml. ALP ranged from 72 to 9518 U/l, serum testosterone from 0.7 to 41.7 nmol/l. Sixty-
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one percent of the patients had T3 and 29% T4 tumors. According to the WHO 
classification, 58% had intermediate, 30% poorly, and 11% well differentiated cancer. Sixty-
one percent of patients had a metastatic disease. Mean and median PSA, mean and median 
ALP, proportion of T4 tumors, proportion of poorly differentiated cancers, proportion of 
metastatic disease, and the number of skeletal hot spots were significantly higher in the 
group A than group B (Table 5). Mean and median serum testosterone levels were slightly 
lower in the group A at entry. The value of the baseline testosterone was not significant in 
the logistic regression multivariate analysis (p=0.180). 
 
Table 5.  PSA, ALP, T-category, M-category and hot spots in logistic regression (multivariate) 
analysis. 
 B p OR 95% CI 
PSA 
ALP 
T-category(T1-2) 
T-category(T3) 
T-category(T4) 
M-category 
Hot spots 
Constant 
-0.001 
-0.000 
 
-0.424 
-0.820 
-0.696 
-0.456 
2.280 
<0.001 
0.007 
0.013 
0.141 
0.007 
0.001 
0.039 
<0.001 
0.999 
1.000 
 
0.654 
0.441 
0.499 
0.634 
9.775 
0.998−0.999 
0.999−1.000 
 
0.372−1.151 
0.243−0.799 
0.329−0.755 
0.411−0.977 
B=regression coefficient; OR=odds of risk ratio; CI=confidence interval. Testosterone dropped 
out because in previous logistic regression analysis p-value was non-significant (p=0.180).   
  
5.2 COMPARISON OF INTERMITTENT AND CONTINUOUS ANDROGEN 
DEPRIVATION 
Of the enrolled 852 patients, 274 were randomised to receive IAD (49.5%) and 280 CAD 
(50.5%). One patient refused to be entered to the randomised IAD. Median follow-up time 
from randomisation was 65 months, with a maximum of 11.6 years; 53% of the patients 
were followed up for longer than 5 years, with no patient lost to follow-up. 110 patients 
(19.9%) continued >5 years in the trial before TF: 52 (19.0%) in the IAD and 58 (20.7%) in the 
CAD arm (p=0.50). 
5.2.1 Patient characteristics 
The characteristics of the IAD and CAD patients are presented in table 6. Mean age was 
71.5 years, with no difference in the distributions of patients in the different age groups 
(<50, 50−59, 60−69, 70−79, ≥80 years). Treatment arms were comparable with respect to 
advancement of PC, differentiation grade, PSA, ALP, testosterone, performance status, 
concurrent diseases, PSPA-score, and QoL. At entry, 40% and 38% of patients in the IAD 
and CAD arm had PSA <20 ng/ml, 60% and 62% had PSA ≥20 ng/ml (p=0.64). Of the 
randomised patients, 79% achieved PSA nadir ≤4 ng/ml. 
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Table 6. Patient characteristics at entry and at randomisation in intermittent and continuous 
treatment arms.  
  Intermittent  
n=274, (%) 
 
Continuous  
n=280, (%) 
 
Total  
n=554, (%) 
 
    p 
Age  <70 years 
≥70 years 
102 (37.2) 
172 (62.8) 
 
102 (36.4) 
178 (63.6) 
 
204 (36.8) 
350 (63.2) 
mean 71.5 yr 
 
0.85* 
M-Category 
 
M0  
M1 
140 (51.1) 
134 (48.9) 
 
137 (48.9) 
143 (51.1) 
 
277 (50.0) 
277 (50.0) 
 
0.61* 
 
TM-Category 
  
  
  
T1-2M0 
T1-2M1 
T3M0 
T3M1 
T4M0 
T4M1 
 
7 (2.5) 
20 (7.3) 
101 (36.9) 
81 (29.6) 
32 (11.7) 
33 (12.0) 
12 (4.3) 
28 (10.0) 
99 (35.3) 
73 (26.1) 
26 (9.3) 
42 (15.0) 
19 (3.4) 
48 (8.7) 
200 (36.1) 
154 (27.8) 
58 (10.5) 
75 (13.5) 
0.22* 
0.31 
0.71 
0.36 
0.43 
0.37 
WHO Grade 
  
  
GI  
GII  
GIII 
 
32 (11.7) 
175 (63.9) 
67 (24.5) 
43 (15.4) 
164 (58.6) 
73 (26.1) 
75 (13.5) 
339 (61.2) 
140 (25.3) 
 
0.34* 
Gleason† 
 
≤6 
3+4 
4+3 
8-10 
Total 
 
13 (5.3) 
32 (13.1) 
57 (23.4) 
142 (58.2) 
244 (100.0) 
 
15 (6.1) 
33 (13.4) 
55 (22.3) 
144 (58.3) 
247 (100.0) 
 
28 (5.7) 
65 (13.2) 
112 (22.8) 
286 (58.2) 
491 (100.0) 
 
0.98* 
PSA at baseline  
(ng/ml) 
 
 
mean (SD)  
median 
95% CI 
116.0 (173.4) 
64.0 
95.29-136.61 
 
186.3 (454.4) 
70.3 
132.75-239.85 
 
151.5 (n=554) 
67.6 
 
 
0.31** 
 
PSA at 6 mos  
(randomisation)  
(ng/ml) 
mean (SD) 
median 
95% CI 
2.37 (2.43) 
1.40 
2.08-2.66 
 
2.45 (2.48) 
1.60 
2.16-2.74 
 
 
0.71*** 
 
Testosterone at  
baseline 
(nmol/l) 
 
mean (SD)  
median 
95% CI 
15.25 (5.87)  
14.58 
14.53-15.97 
(n=261) 
14.94 (6.30)  
14.30 
14.18-15.70 
(n=267) 
15.1 (n=528) 
14.5 
 
 
 
0.56*** 
 
Testosterone at  
6 mos (nmol/l) 
 
mean (SD) 
median 
95% CI 
0.84 (0.44)  
0.80 
0.79-0.90 
(n=261) 
 
1.05 (2.18)  
0.78 
0.79-1.32 
(n=267) 
 
0.27** 
ALP (IU/l) 
 
mean (SD)  
median 
95% CI 
 
256.1 (354.9)  
176.5 
213.38-298.90 
(n=268) 
297.9 (443.1)  
171.0 
245.38-350.39 
(n=277) 
277 (n=545) 
173 
 
 
 
0.22*** 
 
* 2-test ; **median test; ***t-test; †defined by two pathologists for 491 patients; 
M=metastatic status; T=tumour stage (local advancement); WHO=World Health Organisation; 
PSA=prostate-specific antigen; SD=standard deviation; CI=confidence interval; ALP=alkaline 
phosphatase.  
 
 
5.2.2 Intermittent androgen deprivation treatment 
In the IAD arm, the median number of cycles was 3 (0−14) with one patient reaching the 
14th cycle. TOFF duration decreased from cycle to cycle, from a mean of 33.5 weeks in the 1st 
cycle to 14.7 weeks in the 10th cycle, with the longest duration being 312.0 weeks in the 1st 
cycle (Fig. 5). Plasma testosterone showed a recovery at the end of each TOFF, but without 
reaching the level at the end of the previous TOFF. Thus, mean and median testosterone at 
the end of TOFFs decreased from cycle to cycle. At entry, 81.2% of patients in the IAD arm 
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had testosterone ≥10 nmol/l, decreasing to 47.4% at the end of the 10th TOFF (Fig. 6). During 
the 12 first TONs, 81.6−100% of IAD patients reached a serum testosterone level <1.5 nmol/l, 
for the rest of them, testosterone levels were between 1.5 and <7 nmol/l. 
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Figure 5. Mean and median duration of the treatment-off phase of each cycle in the intermittent 
arm. 
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Figure 6. Mean and median testosterone at the end of each treatment-off and treatment-on 
phase in the intermittent arm; toff=treatment-off phase; ton=treatment-on phase. 
 
 
5.2.3 Progression-free, overall, prostate cancer-specific, and treatment failure survival 
During the trial, 492 patients (88.8%) were withdrawn. For 372, this was due to death or 
disease progression: 177 (64.6%) in the IAD and 195 (69.6%) in the CAD arm (p=0.76). At the 
end of the study, 392 patients of 554 (71%) had died: 186 (68%) in the IAD and 206 (74%) in 
the CAD arm (p=0.12). There were 248 (45%) PC deaths (63% of all deaths): 117 (43%) in the 
IAD and 131 (47%) in the CAD arm (p=0.29). Among patients with endpoints, median times 
from randomisation to progression in the IAD and CAD arms were 34.5 and 30.2 months, 
to death (all-cause) 45.2 and 45.7 months, to PC death 45.2 and 44.3 months, and to TF 29.9 
and 30.5 months. No statistically significant differences were apparent in PFS, OS, PCS, or 
TFS between the treatment arms (Fig. 7), but the risk analysis showed a hazard ratio of 
1.08−1.17 for CAD (Table 7). PSA level at randomisation (PSA <1.0; 1.0−4.0; >4.0 ng/ml) was 
associated with PFS (p=0.002), PCS (p=0.006), and TFS (p<0.001), but not with OS (p=0.290) in 
the whole study population (Fig. 8). The differentiation grade according to the Gleason 
scores also had an impact on PFS, OS, PCS, and TFS (p<0.001) (Fig. 9). 
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Figure 7. Kaplan-Meier curves for progression-free, overall, prostate cancer-specific, and 
treatment failure survival in intermittent and continuous treatment arms; p-values for log-rank 
tests. 
 
 
Table 7. Hazard ratios and 95% confidence intervals (univariate unadjusted cox regression 
model) between intermittent and continuous treatment arms. 
 HR 95% CI p-value 
Progression  
IAD 
CAD 
 
1 
1.08 
 
 
0.90-1.29 
 
 
0.43 
Death (all-cause)  
IAD 
CAD 
 
1 
1.15 
 
 
0.94-1.40 
 
 
0.17 
Prostate cancer death 
IAD 
CAD 
 
1 
1.17 
 
 
0.91-1.51 
 
 
0.21 
Treatment failure 
IAD 
CAD 
 
1 
1.13 
 
 
0.95-1.35 
 
 
0.17 
HR=hazard ratio; CI=confidence interval; IAD=intermittent treatment arm; CAD=continuous 
treatment arm. 
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Figure 8.  Kaplan-Meier curves for progression-free, overall, prostate cancer-specific, and 
treatment failure survival by prostate-specific antigen (PSA) at randomisation in the trial 
population. PSA <1.0 (n=206), 1.0−4.0 (n=229), >4.0 ng/ml (n=118); p-values for log-rank 
tests. One patient refused the intermittent trial therapy (n=553). 
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Figure 9. Kaplan-Meier curves for progression-free, overall, prostate cancer-specific, and 
treatment failure survival by differentiation grade of Gleason scores 6−7 (n=205) and 8−10 
(n=286). The p-values are <0.001 (the log-rank test).  
 
 
5.2.4 Quality of life, adverse events, adverse drug reactions, and PSPA-score 
Treatment arms were comparable as regards QoL at entry and at randomisation (Mann-
Whitney U-test, MWU). They were also balanced with respect to concurrent diseases that 
might predispose towards cardiac and vascular (CV) events or fractures. Eight patients in 
the IAD arm (2.9%) and 11 in the CAD arm (3.9%) used some form of bone-specific 
treatment during the trial (p=0.51). The response rates to the QoL questionnaire domains 
1−9 were 86−92 % at entry and at randomisation, it was at lowest 73% and 69% in the IAD 
and CAD arm during the first five cycles. 
   According to MWU and 0.5 SD rule, the most-frequently detected significant differences 
in QoL between treatment arms were related to activity limitation, physical capacity, and 
sexual functioning, favouring IAD (Fig. 10). This was also confirmed by the repeated 
measures analysis of variance. A non-significant trend in favour of IAD was seen also in 
other domains, except sexuality. The response rate for the last domain (sexuality) was low. 
The proportion of respondents in the domain 9 (sexual functioning), who continued to the 
last domain 10 and reported any sexual activity during the past month, was 48.8% in the 
IAD and 40.1% in the CAD arm at entry, but decreased in both arms thereafter. In the IAD 
arm, the proportion of respondents was clearly higher at the end than in the beginning of 
each TOFF. In the CAD arm, the response rate was approximately 20%. 
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Figure 10. Differences in quality of life between treatment arms according to the Mann-Whitney 
U-test (A-C; *p<0.05) and the 0.5 standard deviation rule (D-F) in the domains of activity 
limitation, physical capacity, and sexual functioning. Lower scores indicate better health in 
activity limitation and physical capacity, higher scores in sexual functioning. SD=standard 
deviation; toff=treatment-off phase; ton=treatment-on phase.  
 
    
   The treatment arms did not differ from each other in the prevalence of adverse events. 
Cardiac and vascular (CV) events were the most prevalent AEVs, with 154 in the IAD and 
162 in the CAD arm. Table 8. shows the number of patients suffering from any 
cardiovascular SAE or bone fracture, those withdrawn from the trial or who died because 
of SAE. In the final survival analysis, 78 patients of 554 (14.1%) died from any CV cause 
(20% of all 392 deaths): 35 in the IAD (12.8%) and 43 in the CAD arm (15.4%) (p=0.38). 
   Hot flushes or sweating during nighttime were the most commonly reported ADRs 
during the trial: 129 patients (47.1%) in the IAD and 141 (50.4%) in the CAD arm (p=0.44). 
Erectile dysfunction (ED) and depressed mood were reported more often in the IAD than 
CAD arm: 15.7 vs 7.9% (p=0.0042) and 2.2 vs 0% (p=0.038). Mean PSPA-scores at entry were 
1.00 in the IAD and 1.01 in the CAD arm (p=0.94). No significant differences between 
treatment arms emerged during the trial, with the exception of the 6th TON (0.73 vs. 1.33, 
p=0.01), the 7th TOFF (0.82 vs. 1.44, p=0.02), and the 8th TON (0.84 vs. 1.56, p=0.04), in favour 
of IAD. 
 A D 
 C 
E 
 
F 
 B 
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Table 8. Number of patients experiencing serious adverse events or adverse drug reactions, 
withdrawing from the trial, or dying because of an adverse event. 
Patients  
IAD 
(n=274) 
n (%) 
CAD 
(n=280) 
n (%) 
Total 
(n=554) 
n(%) 
p 
with cardiovascular SAEs 87 (31.8) 95 (33.9) 182 (32.9) 0.59 
with bone fractures 19 (6.9) 15 (5.4) 34 (6.1) 0.44 
withdrawn because of any SAE or ADR 57 (20.8) 62 (22.1) 119 (21.5) 0.70 
withdrawn because of cardiovascular SAE 25 (9.1) 29 (10.4) 54 (9.7) 0.62 
died because of any SAE 45 (16.4) 50 (17.9) 95 (17.1) 0.65 
died because of cardiovascular SAE 21 (7.7) 24 (8.6) 45 (8.1) 0.70 
SAE=serious adverse event; ADR=adverse drug reaction; IAD=intermittent treatment arm; 
CAD=continuous treatment arm. 
 
 
5.3 COMPARISON OF INTERMITTENT AND CONTINUOUS ANDROGEN 
DEPRIVATION, AND QUALITY OF LIFE BETWEEN PATIENTS WITHOUT 
(M0) AND WITH METASTASIS (M1) 
 
5.3.1 Patient characteristics 
IAD and CAD treatment arms were comparable with each other in the subgroups of 
patients with M0 and M1 disease (Table 9). 
 
5.3.2 Intermittent androgen deprivation treatment 
Mean TOFF duration in the IAD arm decreased almost linearly from cycle to cycle in M0 
and M1 groups from 37.6 and 29.1 weeks in the 1st cycle to 10.4 and 9.1 weeks in the 12th 
cycle (Fig. 11).  
 
5.3.3 Progression-free, overall, cancer-specific, and treatment failure survival 
Of our 554 patients, 492 (88.8%) had to withdraw from the trial (TF), 231 from the M0 and 
261 from the M1 group. Cumulative percentages of TF in the M0 vs M1 group were first 
year: 9.0 vs 31.8%; second year: 19.8 vs 53.8%; and third year: 36.0 vs 63.9% (p<0.001). The 
main reasons for TF were either death or disease progression in 372 patients: 166 (59.9%) in 
the M0, and 206 (74.4%) in the M1 group (p=0.004). At the end of the study, 392 patients 
(71%) had died: 161 (58%) in the M0, and 231 (83%) in the M1 group (p<0.001), with 82 PC 
deaths (30%) in the M0, and 166 (60%) in the M1 (p<0.001).  Mean and median times from 
randomisation to progression, death (overall), PC death, and TF are shown in table 10. 
Differences in PFS, OS, PCS, and TFS between IAD and CAD and between the subgroups of 
M0 and M1 are described in Figure 12. Risk analysis showed significant differences 
between the M0 and M1 subgroup but not between IAD and CAD, although a minor 
advantage was seen from IAD (Table 11). 
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Table 9. Patient characteristics at entry and at randomisation in intermittent and continuous 
treatment arms in the subgroups of patients without and with metastasis. 
 M0 - IAD 
n=140 
(25.3%) 
M0 - CAD 
n=137 
(24.7) 
p 
(M0) 
M1 - IAD 
n=134 
(24.2) 
M1 - CAD 
n=143 
(25.8) 
p 
(M1) 
Age 
  < 70 years 
  ≥ 70 years 
  mean 
 
41 (29.3) 
99  (70.7) 
72.9 
 
51 (37.2) 
86 (62.8)   
72.1 
0.162* 
 
61 (45.5) 
73 (54.5) 
70.6 
 
51 (35.7) 
92 (64.3) 
72.4 
 
0.095* 
TM-Category 
  T1-2 
  T3 
  T4 
 
7 (5.0) 
101 (72.1) 
32 (22.9) 
 
12 (8.7)  
99 (72.3) 
26 (19.0) 
 
0.382* 
 
 
20 (14.9) 
81 (60.5) 
33 (24.6) 
 
28 (19.6) 
73 (51.0) 
42 (29.4) 
 
0.281* 
WHO Grade 
  GI  
  GII  
  GIII 
 
17 (12.1) 
95 (67.9) 
28 (20.0) 
 
23 (16.8) 
86 (62.8) 
28 (20.4) 
0.518* 
 
15 (11.2) 
80 (59.7) 
39 (29.1) 
 
20 (14.0) 
78 (54.5) 
45 (31.5) 
 
0.645* 
Gleason† 
   ≤6 
   3+4 
   4+3 
   8-10 
 
 
10 (8.1) 
20 (16.1) 
35 (28.2) 
59 (47.6) 
(n=124) 
 
9 (7.5) 
21 (17.5) 
33 (27.5) 
57 (47.5) 
(n=120) 
0.991* 
 
3 (2.5) 
12 (10.0) 
22 (18.3) 
83 (69.2) 
(n=120) 
 
6 (4.7) 
12 (9.5) 
22 (17.3) 
87 (68.5) 
(n=127) 
 
0.826* 
PSA at baseline (ng/ml) 
   mean (SD) 
   median 
   95% CI 
 
67.4 (58.7) 
52.2 
57.5-77.2 
 
74.0 (58.2) 
54 
64.1-83.8 
0.674** 
 
166.7 (230.3) 
82.4 
127.37-206.1 
 
293.3 (615.3) 
106.0 
192.2-395.6 
0.104** 
PSA at 6 mos (ng/ml) 
  mean (SD) 
  median 
  95% CI 
 
2.21 (2.25) 
1.3 
1.83-2.59 
 
 
2.32 (2.45) 
1.51 
1.91-2.74 
 
0.697*** 
 
2.53 (2.61) 
1.45 
2.09-2.98 
 
2.55 (2.50) 
1.7 
2.14-2.97 
 
0.953*** 
Testosterone at 
baseline (nmol/l) 
  mean (SD)  
  median 
  95% CI 
 
 
 
15.38 (5.95) 
14.85 
14.37-16.40 
(n=134) 
 
 
 
16.09 (6.14) 
15.2 
15.03-17.14 
(n=133) 
0.342*** 
 
 
15.11 (5.81) 
14.0 
14.09-16.13 
(n=127) 
 
 
13.80 (6.28) 
13.00 
12.73-14.87 
(n=134) 
0.081*** 
Testosterone at  
6 mos (nmol/l) 
  mean (SD)  
  median 
  95% CI 
 
 
 
0.84 (0.56) 
0.80 
0.74-0.93 
(n=133) 
 
 
 
0.96 (1.55) 
0.80 
0.70-1.23 
(n=132) 
0.843** 
 
 
0.89 (0.44) 
0.80 
0.81-0.96 
(n=128) 
 
 
1.18 (2.69) 
0.76 
0.72-1.64 
(n=135) 
0.171** 
ALP (IU/l) 
  mean (SD)  
  median 
  95% CI 
 
 
162.3 (46.7) 
151.0 
154.4-170.3 
(n=136) 
 
 
163.7 (48.0) 
159.0 
155.5-171.8 
(n=135) 
0.820*** 
 
352.8 (485.6) 
205.5 
269.2-436.4 
(n=132) 
 
425.5 (590.3) 
209.5 
327.6-523.4 
(n=142) 
0.269*** 
* 2-test ; **median test; ***t-test; †defined by two pathologists for 491 patients; T=tumour 
stage (local advancement); WHO=World Health Organisation; PSA=prostate-specific antigen; 
SD=standard deviation; CI=confidence interval; ALP=alkaline phosphatase; IAD=intermittent 
treatment arm; CAD=continuous treatment arm; M0=non-metastatic patient subgroup; 
M1=metastatic patient subgroup. 
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Figure 11. Mean duration of the treatment-off phase and the number of patients without (M0) 
and with (M1) metastasis in the intermittent arm. 
 
 
 
Table 10. Time (months) to progression, death (all-cause), prostate cancer death, and 
treatment failure in patients with non-metastatic (M0) and metastatic (M1) prostate cancer. 
Patient 
groups 
Time to 
progression 
 
Time to death Time to prostate 
cancer death 
Time to treatment 
failure 
(n) 
Mean ±SD 
(range)/ median 
(n) 
 
Mean ±SD 
(range)/ median 
(n) 
Mean ±SD 
(range)/ median 
(n) 
Mean ±SD 
(range)/ median 
(n) 
M0 
(277) 
 
 
M1 
(277) 
49.4 ±28.8 
(1.2-117.8)/ 46.8 
(208) 
 
31.0±27.5 
(0.7-115.7)/ 21.4 
(253) 
 
57.1±29.9 
(2.0-121.7)/ 57.6 
(161) 
 
44.6±27.5 
(2.9-127.2)/ 40.3 
(231) 
57.5±29.9 
(7.9-113.9)/ 59.5 
(82) 
 
44.3±27.5 
(4.7-127.2)/ 40.7 
(166) 
45.9±27.7 
(1.2-117.8)/ 41.9 
(231) 
 
29.1±26.4 
(0.0-115.7)/ 20.0 
(261) 
M0 – IAD 
(140) 
 
 
M0 – CAD 
(137) 
 
49.2±28.4 
(1.2-113.3)/ 46.6 
(103) 
 
49.6±29.2 
(2.0-117.8)/ 46.9 
(105) 
57.6±30.2 
(6.6-121.7)/ 62.2 
(76) 
 
56.8±29.7 
(2.0-117.8)/ 53.7 
(85) 
61.4±29.1 
(14.5-113.9)/ 63.9 
(37) 
 
54.3±30.4 
(7.9-111.4)/ 53.6 
(45) 
45.4±28.3 
(1.2-113.3)/ 40.4 
(113) 
 
46.4±27.2 
(2.0-117.8)/ 43.6 
(118) 
 
M1 –IAD 
(134) 
 
 
M1 – CAD 
(143) 
32.0±27.0 
(0.9-112.9)/ 23.2 
(122) 
 
30.1±28.0 
(0.7-115.7)/ 20.0 
(131) 
 
45.1±27.4 
(6.6-127.2)/ 42.0 
(110) 
 
44.1±27.8 
(2.9-119.2)/ 40.1 
(121) 
 
45.0±27.8 
(6.6-127.2)/ 40.7 
(80) 
 
43.7±27.4 
(4.7-119.2)/ 41.9 
(86) 
29.3±26.5 
(0.0-112.9)/ 20.7 
(124) 
 
29.0±26.5 
(0.0-115.7)/ 19.9 
(137) 
IAD=intermittent androgen deprivation; CAD=continuous androgen deprivation; SD=standard 
deviation.  
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Figure 12. Kaplan-Meier curves for progression-free, overall, prostate cancer-specific, and 
treatment failure survival in patients with non-metastatic (M0) and metastatic (M1) prostate 
cancer in intermittent (Int) and continuous (Cont) treatment arms.; p-values for log-rank tests. 
 
p = 0.73 
p = 0.46 
p = 0.37 
p = 0.30 
p = 0.64 
p = 0.27 
p = 0.31 
p = 0.47 
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Table 11. Risk analysis with a univariate unadjusted Cox regression model. 
 
HR 95% CI 
 
p-value* 
 
Progression  
M0 -IAD (n=103) 
     -CAD (105) 
 
M1 -IAD (122) 
     -CAD (131) 
 
1 
1.05 
 
2.05 
2.26 
 
 
0.80-1.37 
 
1.58-2.67 
1.75-2.93 
 
 
0.74 
 
<0.001 
<0.001 
 
Death (all-cause)  
M0 -IAD (76) 
     -CAD (85) 
 
M1 -IAD (110) 
     -CAD (121) 
 
1 
1.18 
 
2.25 
2.50 
 
 
0.87-1.61 
 
1.68-3.01 
1.87-3.33 
 
 
0.29 
 
<0.001 
<0.001 
 
Prostate cancer death 
M0 -IAD (37) 
     -CAD (45) 
 
M1 -IAD (80) 
     -CAD (86) 
 
1 
1.29 
 
3.34 
3.63 
 
 
0.84-1.99 
 
2.26-4.94 
2.46-5.34 
 
 
0.25 
 
<0.001 
<0.001 
 
Treatment failure 
M0 -IAD (113) 
     -CAD (118) 
 
M1 -IAD (124) 
     -CAD (137) 
 
1 
1.10 
 
1.88 
2.17 
 
 
0.86-1.44 
 
1.46-2.43 
1.69-2.79 
 
 
0.43 
 
<0.001 
<0.001 
 
HR=hazard ratio; CI=confidence interval; M0=non-metastatic disease; M1=metastatic disease; 
IAD=intermittent treatment arm; CAD=continuous treatment arm; *p-values for comparison 
with a reference of M0-IAD. 
 
 
5.3.4 Quality of life, adverse events, and adverse drug reactions 
Response rates for the QoL questionnaire domains 1−9 were 84−92 % at entry and at 
randomisation in both subgroups, 24−48% of patients reported some type of sexual activity 
(domain 10) at entry. According to MWU, QoL was significantly worse among M1 than M0 
patients at entry in all other domains, except overall health (p=0.08), sexual functioning 
(p=0.70), and sexuality (p=0.61). The differences disappeared during the trial. Sexual 
functioning was significantly worse in the CAD than IAD arm among M1 patients at entry 
(p=0.03).  According to the 0.5 SD rule, ADT (IAD or CAD) had a beneficial effect on QoL in 
the M1 group in the domains of pain, activity limitation, and social functioning; and in both 
groups in emotional well-being (Fig. 13). IAD offered some extra benefit in terms of activity 
limitation and social functioning. Similarly, a mild beneficial effect of ADT was evident on 
bed disability in M1 patients, without any clear difference between IAD and CAD. A 
deleterious effect of ADT on QoL occurred in physical capacity in the M0 group, especially 
with CAD; and in sexual functioning in both groups, with IAD offering some recovery 
during TOFFs (Fig. 14). 
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Figure 13. Changes in quality of life in the groups of locally advanced (M0) and metastatic (M1) 
prostate cancer patients on intermittent (IAD) or continuous (CAD) androgen deprivation 
according to the 0.5 standard deviation (SD) rule. Lower scores indicate better health in the 
domains of pain and activity limitation; higher scores indicate better health in social functioning 
and emotional well-being. 
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Figure 14. Changes in quality of life in the groups of locally advanced (M0) and metastatic (M1) 
prostate cancer patients on intermittent (IAD) or continuous (CAD) androgen deprivation 
according to the 0.5 standard deviation (SD) rule. Lower scores indicate better health in the 
domains of bed disability and physical capacity; higher scores indicate better health in sexual 
functioning. 
 
 
   In the M0 and M1 groups, 317 and 236 SAEs were recorded during the trial, overall, with 
CV events and pneumonia being the most prevalent. As a whole, 101 (36.5%) in the M0 
group and 81 (29.2%) in the M1 had CV AEVs (p=0.07). Of the 78 patients dying from any 
CV cause (20% of all 392 deaths), 40 died in the M0 (14.4%) and 38 in the M1 group (13.7%) 
(p=0.81). Bone fractures occurred in 16 (5.8%) and 18 (6.5%) patients (p=0.72). Hot flushes or 
night sweats in 152 (54.9%) vs 120 patients (43.3%) (p=0.007) and erectile dysfunction (ED) 
in 39 (14.1%) vs 26 patients (9.4%) (p=0.086) were reported more often in the M0 group. No 
statistically significant difference emerged in the number of patients reporting other ADRs, 
such as depression, gynaecomastia, decreased libido, or fatigue. As a consequence, 119 
patients had to withdraw from the trial because of SAE or ADR, 68 (24.5%) from the M0 
and 51 (18.4%) from the M1 group (p=0.08).  
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6 Discussion 
6.1 STUDY SAMPLE AND DESIGN 
6.1.1 Study sample 
The FinnProstate Study VII (FPVII) was planned to be conducted as a randomised 
multicenter clinical trial including patients with metastatic PC (M1).  Based on the previous 
trial (Zeneca study 1166301/1509), the median time to progression for patients with 
metastatic PC (PSA >60 ng/ml), treated with continuous goserelin and who did not progress 
during the first 6 months, was 14.5 months. The primary analysis was estimated to be 
completed 36 months after the cessation of recruitment. In order to detect a difference of 
five months in the median time to progression with 90% power, it was calculated that a 
total of 600 patients (300:300) would be required. However, because of the slow recruitment 
rate, the inclusion criteria were widened in June 1998 to include patients with locally 
advanced or recurrent PC. In the Zeneca study 176334/0307, the median time to progression 
for patients with PSA >20 ng/ml and receiving continuous ADT was 35 months. With this 
more heterogeneous patient population, fewer events were expected to occur in the follow-
up time previously specified as 36 months.  In order to estimate the likely event rate in this 
new population, the median time to progression was calculated to be 20.5 months. Thus, to 
detect a hazard ratio of 1.345 with 90% power with 600 patients, the primary analysis was 
estimated to be completed 50 months after completion of recruitment (after a minimum 
follow-up of 50 months), with a difference of seven months in the median time to 
progression being capable of being detected. Thus, the widened inclusion criteria meant a 
more heterogeneous patient population and a longer follow-up than expected, although no 
patient with biochemical PSA relapse after curative intended treatment was enrolled. 
Ultimately, 852 patients were enrolled and 554 patients could be randomised, only slightly 
less than calculated for the desired statistical power. It is outstanding that none of our 
patients was lost to follow-up during the trial. 
   Many of the previous pilot and phase II trials had more heterogeneous patient 
populations with recurrent, localised, locally advanced, and metastatic PC, which 
complicates the comparison with previous trials and results. However, some trials included 
only patients with locally advanced and/or metastatic PC, making the patient population 
less heterogeneous.3, 255, 266, 271, 277 Most of the phase III trials have included only patients with 
locally advanced and/or metastatic PC, as in the present study.259, 292-295, 298 
   The randomisation process succeeded well. Patients were evenly distributed and 
treatment arms were equivalent with each other. No stratification was done. For some 
unknown reason, PSA levels were somewhat higher at entry in the CAD arm and in the 
M1-CAD arm but no longer at the time of randomisation.  
 
6.1.2 Study design 
The concept of treating cancer with intermittent hormonal therapy arouse in the 1970s.263 
Planning of the FPVII trial was started in the early 1990s. By then, only a few trials in 
experimental animals and a couple of clinical pilot studies had been completed and no 
randomised trials had been published. 
 
6.1.2.1 Treatment regimen 
A well-documented LHRH analogue, goserelin acetate (Zoladex®, AstraZeneca), was 
chosen to be used for 24 weeks as induction treatment and during TONs. The steroidal 
antiandrogen, cyproterone acetate (CPA), was used only temporarily for 12.5 days in 
connection with the first LHRHa implant to minimise the flare reaction. CPA was chosen 
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because of its short half-life (T½) which meant that it quickly established a steady state. In 
most of the other clinical trials, MAB was used during initial and later TONs. However, the 
benefit of MAB in comparison with surgical or chemical castration alone has not been 
proved.197, 198 A few trials have used the LHRH analogue alone256, 276 or antiandrogen 
monotherapy,283, 295 mostly with recurrent PC after curative-intended teatment. In three 
trials, the use of AA with LHRHa was optional.277, 281, 287, 288 In two of the randomised trials, 
only a short-term AA was used with an LHRHa to avoid flare reaction, as in this present 
study.250, 261 Hence, the treatment regimen varied from study to study, complicating the 
comparison of trials with each other. 
 
6.1.2.2 The initial treatment-on phase, the cut-offs for ADT withdrawal and resumption 
The duration of the induction ADT is a matter of debate. There is controversy about the 
criteria for withdrawal and for reintroduction of therapy. The initial TON was chosen as 24 
weeks, PSA cut-off for withdrawal of ADT <10 ng/ml or ≤50% of the baseline (when 
<20ng/ml), and for resumption >20.0 ng/ml or above baseline. However, most of the 
randomised patients, that is 79%, reached PSA level <4 ng/ml during the run-in period, 
which has been the cut-off level in many other trials. 
   In other trials, the duration of the initial TON has ranged from 3 to 12 months, although it 
has commonly been between 6 and 9 months. The most often used PSA cut-off for ADT 
withdrawal is 4 ng/ml and for resumption 10 to 20 ng/ml, depending on the baseline PSA 
and the nature of patient's PC (recurrent biochemical failure, previously untreated, 
localised, locally advanced, or metastatic). In some series, either biochemical failure or PSA 
velocity has been considered as the trigger point, whereas in others, clinical recurrence or 
recurrence of symptoms has been required prior to the reintroduction of ADT. When the 
present trial was started in 1997, there were no evidence based values for PSA cut-off levels 
or the duration of the induction ADT, especially with advanced PC and high baseline PSA 
levels. At that time, only a few phase 2 trials had been published, the first randomised 
study did not appear until 2002.290 So, the cut-off levels of PSA and the duration of 
induction phase were only empirical. 
   Nevertheless, Gleave et al stated that androgen ablation should be continued until 
maximal castration-induced apoptosis and tumor regression had been induced, but halted 
before constitutive development of the androgen-independent phenotype.164 Later, 
Grossfeld et al (2001) proposed that the first nadir PSA should be achieved within an 
average of 6 months,278 whereas Albrecht et al (2003) stated it should occur within a median 
of 19 weeks.266 Thus, the present treatment regimen of 24 weeks seemed appropriate. On the 
other hand, Calais da Silva et al (2009) reported a short-term MAB of only three months as 
having no demonstrated impact on survival.292 
 
6.1.2.3 Quality of life assessment, PSPA-score, adverse drug reactions, and testosterone 
There were no well-documented tools for assessment of QoL in the early 1990s when this 
trial was being planned. It was decided to utilise the Cleary 30-item validated questionnaire 
which was introduced in 1995, shortly before the final study protocol was completed in 
1996. The Cleary instrument was based on two clinical international trials conducted in six 
countries with a total of 550 patients. It was designed for multinational use to explore the 
value of ADT for advanced PC.244 It appears that there are no definitions (minimum) for 
clinically important differences when interpreting the results of the Cleary questionnaire. 
The QCQ-C30 questionnaire was developed at the same time.243 Most trials concerning IAD 
and QoL have used QCQ-C30. Of the randomised trials, de Leval et al (2002) did not use 
any assessment of QoL.290 The PSPA-score was included in the present trial protocol in 
order to have an extra tool for assessment of any differences in QoL between treatment 
arms. However, it is not a validated instrument. 
   PSPA and QoL questionnaire scores were analysed and summarised at the end of each 
TOFF and TON in the IAD arm and at approximately the same time point in the CAD arm. 
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The basis for the time point was as follows: at the end of the TOFF, patients had had the 
maximal duration of time without ADT and a maximal time for recovery of serum 
testosterone before the initiation of a new treatment-on period of at least 24 weeks. The 
duration of TOFF varied from patient to patient and was naturally dependent on cancer 
control and the velocity of PSA increase. The approximate point of time was defined by 
calculating the mean durations of previous cycles and the mean duration of the present 
TOFF or cycle. Patients in the CAD arm were selected by taking into account the visit 
closest to this time point. In the CAD arm, patients without metastases were examined only 
every 24 weeks (when QoL questionnaire was self-administered), although laboratory tests 
were monitored every 12 weeks. For these reasons, the number of patients analysed in the 
CAD arm at each time point varied quite extensively and may have caused some bias. In 
other randomised trials, QoL has been assessed at regular intervals or at fixed points 
regardless of the treatment phase, thus including patients both on treatment and off 
treatment in the IAD arm. This is likely to obscure possible differences between treatment 
arms perhaps masking the benefit of IAD. 
   The QoL questionnaire was self-administered by patients themselves without any help of 
co-investigators or staff. The questionnaires were monitored in the database and not 
analysed until the trial was closed. Thus, the investigators could not have any exerted 
influence on the answers or on the response rates. This is probably the explanation for the 
fact that response rates for all the items in the QoL questionnaire were not 100%. 
   The Mann-Whitney U-test was used to compare the sum of the scores in each domain 
between treatment arms at a certain time point. The 0.5 SD rule was used to find any 
minimally important changes and differences within the treatment arm by comparing the 
magnitude of the change with the baseline SD. The threshold of an important change is 
approximately one half of the baseline SD, a criterion which has been empirically derived.297 
   ADRs were assessed at each visit by their response to the question: “Has anything 
bothered you since your last visit?” No attempt was made to analyse the relief of ADRs 
during TOFF but relied on the QoL analysis in this respect. Thus, only the numbers of 
patients with any ADR in each treatment arm during the trial were estimated, but were 
unable to determine whether IAD offered any relief of an ADR during TOFF. 
   Serum testosterone was measured systematically every 12 weeks in this trial. Mean and 
median testosterone was analysed at the end of each TOFF, which means after a maximal 
time without ADT and maximal time for testosterone recovery, and at the end of each TON, 
which means after at least 24 weeks' exposure for ADT. Mean and median recovery times 
for testosterone were not analysed. In order to report mean and median delay for 
testosterone recovery, testosterone should have been measured at one month or shorter 
intervals. Many of the nonrandomised trials have included testosterone measurement and 
recovery rate analysis. However, not all randomised trials have reported testosterone 
determinations or recovery rates. Calais da Silva et al (2009) measured serum testosterone 
levels only in the subgroups of 192 (IAD) and 178 patients (CAD) at a fixed 3-monthly-
interval.292 
  
6.2 THE ELIGIBILITY OF PATIENTS FOR RANDOMISATION AND IAD 
 
The interim analysis conducted during the run-in period showed that patients with 
advanced PC having a high PSA, ALP and metastatic disease with more than five skeletal 
hot spots did not show an adequate response to ADT.  In other words, the patients with the 
most aggressive and the most advanced PC were not candidates for IAD. A PSA response 
for induction-ADT was essential to determine the patient's eligibility for IAD. This is in 
accordance with other reports.4, 206, 259, 266, 281 Albrect et al (2003) proposed the exclusion of 
patients with more than five hot spots on the bone scan and/or visceral metastases from 
IAD, as only one third of these patients could start three or more treatment cycles in their 
nonrandomised trial.266 Prapotnich et al (2003) showed that patients with bulky tumors, 
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with numerous lymph nodes or bone metastases and initial PSA >100 ng/ml or severe pain 
seemed to achieve only a partial or short-term response and were poor candidates for IAD.4 
Later, they suggested differentiation grade and patient age as being prognostic factors in 
addition to these parameters.286  
   In the present population of enrolled patients, 35% were not eligible for randomisation, 
mainly because they did not exhibit a sufficient PSA response, showed disease progression, 
or died during the run-in phase. In two other randomised trials with only metastatic PC, 
the percentage of patients not eligible for randomisation (with PSA cut-off of 4 ng/ml) was 
33% and 49%.259, 293 Instead, these figures were much better (82% and 99% eligible) in two 
other phase III trials which examined either more heterogeneous patient populations or 
patients with only nonmetastatic recurrent PC.250, 292 
 
6.3 TREATMENT CYCLES IN THE INTERMITTENT ARM 
 
The present median follow-up time was 65 months, with no patient lost to follow-up and 
one patient reaching the 14th cycle during 11.6 years' follow-up. Less than 50% of the IAD 
patients entered the 4th cycle. In other phase III trials, the mean or median follow-up time 
has ranged between 28 months and 9.2 years. The duration of TOFFs and percentage off-
treatment during the cycle decreased in successive cycles throughout the trials. De Leval et 
al (2002) reported the length and percentage of time spent off therapy decreasing by a mean 
of 20 days (0.9%) with each consecutive cycle.290 The mean TOFF in the present trial was 
33.5 weeks (57% of cycle duration) in the first cycle but decreased to 10.0 weeks (27%) in the 
12th cycle; in M0 and M1 subgroups from 37.6 and 29.1 weeks in the 1st cycle to 10.4 and 9.1 
weeks in the 12th cycle. However, the treatment failure rate was much higher in the M1 than 
in the M0 group. These figures are comparable with those in the literature. Crook et al 
(2012) reported longer durations of TOFFs but they enrolled patients with minimally 
extensive recurrent and nonmetastatic PC.250 In summary, the shortening TOFF seems to 
predict future disease progression. 
 
6.4 PROGRESSION-FREE, OVERALL, PROSTATE CANCER-SPECIFIC, AND 
TREATMENT FAILURE SURVIVAL 
 
PFS, OS, PCS, and TFS were equivalent in the two treatment arms.  Though it was not 
possible to detect any significant differences between IAD and CAD, a slight advantage 
from IAD was seen in the risk analysis (HR 1.08−1.17, 95% CI 0.90−1.51, p=0.17−0.43). 
Survival rates were much lower with metastatic than non-metastatic disease, which is not 
surprising, but there was no difference apparent between IAD and CAD. Risk analysis 
revealed again a slight and statistically nonsignificant advantage from IAD in both 
subgroups of M1 and M0. The SEUG trial 9401 detected no difference in OS between IAD 
and CAD but a slightly higher risk for progression and death in the IAD arm. In the 
detailed risk analysis, there was a slight advantage in OS from CAD among 425 M0 patients 
(0.86; 95% CI: 0.65−1.14) but a small disadvantage among 191 M1 patients (1.26; 95% CI: 
0.90−1.78), favouring IAD.292 In the TULP trial, M1 patients on IAD showed a trend towards 
higher progression rates and seemed to fare worse than those with CAD.259 Recently, Mottet 
et al reported no significant differences in PFS or OS between IAD and CAD among 173 
patients with M1 disease.293 The most recent results of the large SWOG 9346 trial of 1535 
randomised M1 patients showed a trend favouring CAD for PCS and OS with a minimally 
extensive disease but could not show the inferiority of IAD, however.294 In summary, no 
significant differences have appeared between IAD and CAD in the treatment of PC. 
   In the present trial, the differentiation grade of PC (Gleason scores ≤7 vs 8−10) had a 
significant impact on PFS, PCS, OS, and on TFS. PSA nadir at randomisation (<1.0; 1.0−4.0; 
>4.0 ng/ml) was also associated with prognosis. These results are in accordance with the 
results of the SEUG trial 9401 and the SWOG 9436 trial.291, 292 PSA nadir and the duration of 
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the first TOFF have been demonstrated to be predictors of the time to clinical progression 
also in other trials.287-289 
 
6.5 QUALITY OF LIFE AND PSPA-SCORE 
 
The present trial showed that IAD did offer some benefits in QoL when compared with 
CAD, especially in the domains of activity limitation, physical capacity, and sexual 
functioning. QoL was significantly worse in most domains in the subgroup of M1 than M0 
at trial entry, evidently due to advancement of PC. The differences disappeared with time. 
On the other hand, the trial treatment showed a beneficial effect on QoL of M1 patients in 
the domains of pain, activity limitation, and social functioning; and of both subgroups in 
emotional well-being. This is probably due to the cancer's response to ADT, resulting in 
relief of emotional and physical distress. In contrast, ADT showed a deleterious effect on 
QoL in terms of physical capacity in M0 patients and for sexual functioning in both groups. 
The advantage of IAD was evident in sexual functioning in both groups, in physical 
capacity in M0 group, and in activity limitation and social functioning in M1 group. 
   These results comparing QoL between M0 and M1 patients are in accordance with 
previous reports. Herr and O`Sullivan (2000) reported that ADT, especially MAB, caused 
fatigue, decreased physical activity, evoked emotional distress, and decreased general 
health in patients with asymptomatic nonmetastatic PC, thus significantly impairing QoL.299 
Kato et al (2007) claimed that ADT improved QoL significantly in the domains of pain, 
vitality, role-emotional health, and mental health in Japanese men with metastatic disease. 
In contrast, vitality declined in patients with localised PC.300 
   Many of the phase III trials have not been able to demonstrate any clear difference in QoL 
between IAD and CAD. Langenhuijsen et al (2011) reported a trend towards more side 
effects, like hot flushes, nausea, constipation, dyspnoea, and depression, from CAD but 
could not detect a consistently significant difference for any single QoL parameter between 
IAD and CAD.259 Likewise, Mottet et al (2012) could identify no clinically relevant 
differences and no general trend in QoL scores between IAD and CAD. However, 
significantly fewer treatment-related AEs occurred in the IAD arm (p=0.042).293 
Furthermore, the results of the JPR7 trial showed only slightly better scores for functional 
domains of physical role and global health with IAD, but the differences were not 
statistically significant. However, IAD was associated with significantly better scores for 
items pertaining to symptoms: hot flashes (p<0.001), desire for sexual activity (p<0.001), 
urinary symptoms (p=0.006), and with a trend towards improvement in the level of fatigue 
(p=0.07).250 Calais da Silva et al (2009) reported fewer major side-effects of hot flushes and 
gynaecomastia in the IAD arm of the SEUG trial 9401. Surprisingly, QoL figures, except for 
sexual quality, were slightly lower with IAD.292 This may be due to the different kinds of 
questionnaires used or cultural differences between the Nordic countries and the 
Mediterranean area. Patients in the Mediterranean area may have experienced more 
anxiety during TOFF when without treatment. Instead, Verhagen et al reported better 
physical and emotional functions but worse cognitive functions with IAD than encountered 
with CAD (p<0.05).295 A recent review of the literature summarised only some safety, 
tolerability, and QoL benefits associated with IAD over CAD.301 Hussain et al (2013) found 
better erectile function and mental health with IAD when compared with CAD at month 
three but not thereafter.294 However, the limitation of these trials is that QoL was assessed at 
regular intervals or at fixed points regardless the treatment phase, thus including patients 
both on treatment and off treatment in the IAD arm. This may have blurred the differences 
between the treatment arms. In the present trial, QoL was analysed at the end of each TOFF 
and TON in the IAD arm and defined approximately the same time point in the CAD arm 
in an attempt to compare the results between IAD and CAD. In addition, the rather low 
number of randomised patients in the trials of Langenhuijsen et al. and Mottet et al. may 
explain the modest impact of IAD on QoL. 
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   According to the MWU-test, the significant differences in QoL between IAD and CAD did 
not emerge constantly during TOFFs but also sometimes during TONs, favouring IAD. This 
may suggest that even a short interruption of ADT compared with CAD might have a 
beneficial effect on QoL over the long term. On the other hand, this may suggest that the 
differences in QoL parameters are not dependent merely on the variations in the 
testosterone level. This is supported by the fact that approximately 20% of the present CAD 
patients reported sexual activity during the past month despite continuous castration. In 
summary, IAD seems to confer some beneficial effects on QoL. 
   In practical terms, no statistically significant differences could be detected in PSPA-scores 
between IAD and CAD. This is probably due to the narrow scale of PSPA-scores. On the 
other hand, the PSA cut-off 20 ng/ml for resumption of ADT was rather low to provoke any 
worsening of symptoms from PC. The value of the PSPA-score was very limited. 
 
6.6 ADVERSE DRUG REACTIONS, ADVERSE EVENTS, AND TESTOSTERONE 
RECOVERY  
 
In the present trial, the number of patients reporting ED and mood depression was higher 
in the IAD arm, which differs from other trials and was unexpected. This may be due to the 
way ADRs were assessed through the question: “Has anything bothered you since your last 
visit?” At entry, 48.8% of patients reported some level of sexual activity in the IAD arm 
compared with 40.1% in the CAD. Patients may have grown accustomed to their symptoms 
and no longer felt bothered, especially those receiving CAD. No attempt was made to 
analyse the relief of ADRs during TOFF, instead relying on QoL analysis in this respect. 
One would have expected the mood to be less depressed at the end of the TOFF with the 
recovery of the testosterone levels. On the other hand, patients may have experienced some 
anxiety during TOFFs being concerned that they were not receiving any specific treatment 
for their PC. In this respect, the anxiety and co-operation of patients have to be taken into 
account when considering IAD. In the present trial, one patient refused to be randomised to 
IAD. No significant differences were detected in the number of other ADT-related 
symptoms. 
   Although the number of adverse events was higher in the CAD arm, there were no 
significant differences between treatment arms in the present trial. No statistically 
significant differences emerged in the prevalence of AEVs or in the number of patients 
suffering from cardiovascular SAEs, nor in the incidence of deaths caused by any SAE or 
CV event. Furthermore, the incidence of bone fractures was practically the same in both 
treatment arms. Calais da Silva et al (2009) reported a trend towards more CV deaths in the 
CAD than IAD arm, with an HR of 1.27 (95% CI: 0.84−1.99).292 In the study of Mottet et al 
(2012), SAEs were reported as often in the CAD as in the IAD arm (29.8% vs 31.3%).293 
Although several factors which have an adverse effect on CV risk have been associated 
with ADT, the association between ADT and CV mortality is still controversial.211, 229 
Nontheless, large population based cohort studies have shown ADT to be associated with 
an excess risk of fractures.235-238 
   In the present study, testosterone levels showed recovery at the end of each TOFF, but did 
not reach the same level as at the end of the previous TOFF. The proportion of patients with 
normalised testosterone levels ≥10 nmol/l during TOFF decreased from cycle to cycle. This 
has been shown also in other trials.259, 260, 293 Crook et al (2012) reported only 35% of patients 
as returning to the pretreatment testosterone level during TOFF, and only 29 % of patients 
who were potent at entry as having recovery of potency.250 As the TOFF duration declines 
from cycle to cycle, patients return to ADT sooner and sooner repeatedly and have less time 
to allow testosterone levels to recover. It seems that testosterone levels are restored more 
slowly than the corresponding PSA increases to the cut-off for resumption of ADT. This, 
probably, explains why no statistically significant differences were found in the incidence 
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of (S)AEs or their consequences between treatment arms despite intermittent dosing and 
shorter exposure time for ADT in the IAD arm. 
 
6.7 COSTS OF THE ANDROGEN DEPRIVATION THERAPY 
 
Orchiectomy has been shown to be the most cost-efficient method of castration over LHRH 
agonists, LHRH antagonist, or maximal androgen blockade, especially when life 
expectancy is more than two years.302-304 However, the use of medical castration is 
increasing. Leuprorelin has been proposed to be the most cost-effective treatment in 
preference to other depot formulation LHRH agonists.305 The LHRH antagonist, degarelix, 
is unlikely to be cost-effective compared to LHRH agonists plus a short-term course with an 
antiandrogen in the treatment of advanced hormone-dependent PC.306 
   Cost-effectiveness analysis was not one of the objectives of the present trial. However, 
IAD is likely to be cost-effective when compared to medical CAD. One-month depot 
therapy with LHRH agonists, as used in Finland, costs approximately 167 €, 3-month 
depots 415 €, and 6-month depots 745 €. The only available LHRH antagonist, degarelix, 
costs 702 € as a starting dose and thereafter 179 € every month. The mean duration of TOFF 
decreased from 33.5 weeks (approximately eight months) in the first cycle to 14.7 weeks (3.5 
months) in the 10th cycle. Thus, the costs saved during these TOFFs would vary from a 
mean of 1336 € to 585 € with LHRH agonists, and from a mean of 1432 € to 627 € with the 
LHRH antagonist. Furthermore, the time of the nursing staff is freed up when no injections 
or implantation of the drug are needed during TOFF which is another factor which should 
be taken into account. However, patients on IAD need closer follow-up at shorter intervals 
during TOFFs. Apparently, the additional PSA tests every 3 months during TOFFs would 
not exceed these savings.   
 
6.8 LIMITATIONS OF THE FINNPROSTATE STUDY VII 
 
A total of 600 patients (300 and 300 in each treatment arm) was calculated to be required for 
statistically powerful analysis and to detect a hazard ratio of 1.345 with 90% power. 
Ultimately, 554 patients were randomised, somewhat less than originally estimated. The 
FPVII study was planned to include patients with metastatic PC (M1).  However, because 
of the slow recruitment rate, the inclusion criteria were widened to enroll patients with 
locally advanced PC which led to a more heterogeneous patient population and longer 
follow-up time. The number of patients in each treatment arm (IAD vs CAD) of the 
subgroups of M0 and M1 (140:137 and 134:143) was rather small, reducing the statistical 
power in the subgroup analysis. 
   The PSA cut-off <10 ng/ml for withdrawal of ADT was different from and higher than in 
many other trials. This allows patients with higher tumour burden to be recruited and 
makes the patient population more heterogeneous than with the cut-off ≤4 ng/ml. However, 
nearly 80% of the randomised patients achieved PSA nadir ≤4 ng/ml. 
   In order to compare QoL between treatment arms at the end of TOFFs and TONs, the 
approximate time point was calculated for the CAD arm. The technique to define the time 
point was somewhat arbitrary and may have caused some bias. Furthermore, there are no 
definitions for clinically important differences in the Cleary questionnaire which 
complicated the analysis of the results. The relief of ADRs during TOFFs was not separately 
analysed but relied on the QoL analysis in this respect.  
   Finally, serum testosterone levels were measured at 3-monthly interval which meant that 
it was not possible to assess mean and median recovery times for testosterone. This would 
have required that testosterone concentrations should have been measured at one-monthly 
or even shorter intervals. 
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6.9 FUTURE PERSPECTIVES 
 
Recently published review papers claim that the use of IAD for treatment of PC can no 
longer be considered experimental but represents an appropriate option for many patients 
requiring ADT for advanced or recurrent PC after biochemical PSA failure after curative-
intended treatment, and for selected patients with metastatic disease.307, 308 Nonetheless, 
further investigations are needed to define in detail the selection of patients who are 
appropriate for IAD, the criteria for withdrawal and resumption of ADT, and the optimal 
type of ADT.  
   Most of the trials have been conducted using LHRH analogues with or without 
antiandrogens. LHRH antagonists could represent a viable alternative since they do not 
provoke the serum testosterone surge and flare phenomenon and by reaching castrate 
testosterone levels more rapidly. Furthermore, other methods of hormonal therapy could 
be examined in intermittent treatment of PC. Antiandrogen monotherapy could be 
considered in treatment of recurrent PC after curative-intended treatment or with 
minimally extensive disease. Estrogens could be a possible option with advanced or even 
castrate-resistant PC,309 as well as could the novel second-generation AR antagonists. 
   IAD can confer economic benefits due to the reduction of pharmaceutical costs during 
TOFF. On the other hand, IAD patients need more careful follow-up during TOFF, which 
means extra costs to the health care system. It would be interesting to conduct a thorough 
cost-effectiveness analysis between IAD and CAD. 
   Finally, there is a need for high-quality QoL evaluation between IAD and CAD, because it 
seems that the main advantage of IAD is not the survival benefit but the positive impact on 
QoL. 
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7 Summary and Conclusions 
The purpose of the FinnProstate Study VII was to compare intermittent and continuous 
androgen deprivation in patients with advanced or metastatic PC in terms of times to 
progression, to death, to PC-specific death, and to treatment failure, as well as comparing 
the effect of these treatment modalities on the quality of life. The aim was to identify the 
kinds of patients most appropriate for IAD, whether IAD could delay the development of 
cancer progression to the castration-resistant status or could prolong survival, and whether 
IAD could offer any benefit for QoL. 
 
Based on the present study, the following conclusions can be drawn: 
 
1. Patients with the most aggressive and the most advanced PC having a high PSA, 
ALP and metastatic disease with more than five skeletal hot spots did not show an 
adequate response to ADT and were not candidates for IAD. A PSA response for 
induction ADT is essential to determine the patient's eligibility for IAD. 
 
2. The long-term results of IAD were equal with CAD in terms of time to progression, 
to death, to PC-specific death, and to treatment failure. It was not possible to detect 
any significant delay in the onset of hormone resistance or improvement in survival 
with IAD. 
 
3. IAD offered benefit in QoL when compared with CAD, especially in the domains of 
activity limitation, physical capacity, and sexual functioning. However, it is worth 
mentioning that the incidence of adverse events was not significantly lower with 
IAD. 
  
4. IAD was as efficient as CAD in treatment of advanced PC in both locally advanced 
disease (M0) and metastatic disease (M1), in terms of PFS, OS, PCS, and TFS. ADT 
improved QoL, with the exception of sexual functioning, to some extent in M1 
patients, with IAD conferring some extra benefits.  
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APPENDIX 1. The FinnProstate Group and Trial Centers. 
Etelä-Karjala Central Hospital, Lappeenranta: Jaakko Permi, Veli-Matti Puolakka; Etelä-
Pohjanmaa Central Hospital, Seinäjoki: Mikael Leppilahti, Markku Leskinen, Timo 
Marttila; Etelä-Savo Central Hospital, Mikkeli: Niilo Hendolin, Tapani Liukkonen; 
Hatanpää hospital, Tampere: Jukka Häkkinen; Helsinki University Hospital: Martti Ala-
Opas, Jussi Aro, Eero Kaasinen, Kari Lampisjärvi, Ilkka Perttilä, Erkki Rintala, Mirja Ruutu, 
Kimmo Taari; Kainuu Central Hospital, Kajaani: Pentti Kemppainen; Keski-Pohjanmaa 
Central Hospital, Kokkola: Pekka Pellinen; Keski-Suomi Central Hospital, Jyväskylä: 
Susanna Laaksovirta, Seppo Lundstedt; Kuopio University Hospital: Sirpa Aaltomaa, 
Antero Heino, Arto Salonen; Kuusankoski District Hospital: Markku Multanen, Markku 
Onali; Lappi Central Hospital, Rovaniemi: Patrik Ehnström, Risto Kauppinen, Matti 
Rauvala; Länsi-Pohja Central Hospital, Kemi: Juhani Ottelin; Oulu University Hospital: 
Pekka Hellström, Jani Kuisma, Olavi Lukkarinen, Aare Mehik, Erkki Ollikkala, Ilkka 
Paananen, Teija Parpala-Spårman, Panu Tonttila; Pietarsaari District Hospital: Christian 
Palmberg; Pohjois-Karjala Central Hospital, Joensuu: Jouko Viitanen; Päijät-Häme Central 
Hospital, Lahti: Kalmer Innos, Taina Isotalo, Kari Lehtoranta, Martti Talja; Satakunta 
Central Hospital, Pori: Heikki Korhonen, Pekka Salminen; Savonlinna Central Hospital: 
Raino Terho; Tampere University Hospital: Martti Aho, Juha Koskimäki, Timo Kylmälä, 
Mika Matikainen, Teuvo Tammela; Turku University Hospital: Kimmo Kuusisto, Matti 
Laato, Martti Nurmi; Vaasa Central Hospital: Erkki Hansson, Susanna Hirsimäki, Peter 
Nylund; Valkeakoski District Hospital: Rauno Kulmala; Ähtäri District Hospital: Juha 
Ervasti. 
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APPENDIX 2. Summary of health-related Quality of Life Questionnaire: Domains and 
Scores. (Gleary et al. Qual Life Res 1995; 4: 207-220) 
 
Assessment of pain (domain 1): 
Q1.  How much pain have you had on average since yesterday? (1-10; 1=no pain; 10=the worst pain you can imagine) 
Q2.  Which number best describes your worst pain during the past 7 days? (1-10;1=no pain; 10=the worst pain ) 
Q3.  Which number best describes your least pain during the past 7 days? (1-10; 1=no pain; 10=the worst pain ) 
Q4.  How much did your pain interfere with your activities during the past 7 days? (1-10; 1=not at all; 10=extremely) 
Assessment of social functioning (domain 2): 
How much of the time, during the past month, has your health limited 
Q5.   your ability to visit with close friends or relatives? (1-6; 1=all of the time; 6=none of the time) 
Q6.   your ability to participate in other social activities? (1-6; 1=all of the time; 6=none of the time) 
Assessment of emotional well-being (domain 3): 
How much of the time, during the past month,  
Q7.   have you been a very nervous person? (1-6; 1=all of the time; 6=none of the time) 
Q8.   have you felt calm and peaceful? (1-6; 1=all of the time; 6=none of the time) 
Q9.   have you felt downhearted and blue? (1-6; 1=all of the time; 6=none of the time) 
Q10. have you been a happy person? (1-6; 1=all of the time; 6=none of the time) 
Q11. have you felt so down in the dumps that nothing could cheer you up? (1-6; 1=all of the time; 6=none of the time) 
Assessment of vitality (domain 4): 
How much of the time, during the past month, 
Q12. did you feel dull or sluggish? (1-6; 1=all of the time; 6=none of the time) 
Q13. did you have or feel energy, pep, or vitality? (1-6; 1=all of the time; 6=none of the time) 
Q14. have you felt tired, worn out, used up, or exhausted? (1-6; 1=all of the time; 6=none of the time) 
Assessment of activity limitations (domain 5): 
Q15. For how many days during the past 7 days did you cut down on the things that you usually do because of  
          your health? (0-7) 
Assessment of bed disability (domain 6): 
Q16. For how many days during the past 7 days did you stay in bed for all or most of the day because of your  
          health? (0-7) 
Assessment of overall health (domain 7): 
Q17. Which number best describes your overall health during the past month? (0-10; 0=worst; 10=perfect) 
Assessment of physical capacity (domain 8): 
How much difficulty have you had because of your health during the past month in doing each of the following activities?  
Q18. Vigorous activities, like lifting heavy objects, running, or participating in sports   
          (1-5; 1=no difficulty; 5=unable to do) 
Q19. Moderate activities, like moving a table, carrying shopping or bowling  (1-5;1=no difficulty; 5=unable to do) 
Q20. Walking uphill or climbing a few flights of stairs (1-5;1=no difficulty; 5=unable to do) 
Q21. Bending, lifting, or stooping (1-5;1=no difficulty; 5=unable to do) 
Q22. Going for a short walk outdoors (1-5;1=no difficulty; 5=unable to do) 
Q23. Shaving, dressing, bathing or showering. (1-5;1=no difficulty; 5=unable to do) 
Assessment of sexual functioning (domain 9): 
How much did the following statement apply to you during the past month? 
Q24. I was interested in having sex. (1-5; 1=not at all; 5=a great deal) 
Q25. I thought others found me sexually attractive. (1-5; 1=not at all; 5=a great deal) 
Q26. I felt sexually attractive. (1-5; 1=not at all; 5=a great deal) 
Q27. Have you tried to engage in any type of sexual activity including masturbation or intercourse during  
          the past month? (1=yes; 2=no)     
         -if you circled the answer “NO”, please skip to the end 
Assessment of sexuality (domain 10): 
How much did the following statement apply to you during the past month? 
Q28. “I had difficulty becoming sexually aroused.” (1-5; 1=not at all; 5=a great deal) 
Q29. “I had difficulty getting or maintaining an erection.” (1-5; 1=not at all; 5=a great deal) 
Q30. “I had difficulty reaching orgasm.” (1-5; 1=not at all; 5=a great deal) 
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APPENDIX 3. Kyselykaavake potilaan elämänlaadusta. 
 
Kivun arviointi (osa-alue 1): 
Ympyröikää se numero, joka parhaiten kuvaa 
1. miten paljon kipua Teillä on keskimäärin ollut eilisen jälkeen. (1-10; 1=ei kipua; 10=pahin kipu, jota voitte kuvitella) 
2. suurinta kipua viimeisen 7 päivän aikana. (1-10; 1=ei kipua; 10=pahin kipu, jota voitte kuvitella) 
3. pienintä kipua viimeisen 7 päivän aikana. (1-10; 1=ei kipua; 10=pahin kipu, jota voitte kuvitella) 
4. miten paljon kipunne häiritsi toimintaanne viimeisen 7 päivän aikana. (1-10; 1=ei häirinnyt; 10=häiritsi voimakkaasti) 
Sosiaalisten toimintojen arviointi (osa-alue 2): 
Kuinka paljon viimeisen kuukauden aikana on sairautenne rajoittanut 
5. vierailujanne läheisten ystävien tai sukulaisten luona? (1-6; 1=kaiken aikaa; 6=ei lainkaan) 
6. osallistumistanne muuhun sosiaaliseen kanssakäymiseen? (1-6; 1=kaiken aikaa; 6=ei lainkaan) 
Tunne-elämän arviointi (osa-alue 3): 
Kuinka usein viimeisen kuukauden aikana 
7. olette ollut hyvin hermostunut? (1-6; 1=kaiken aikaa; 6=ei lainkaan) 
8. olette tuntenut itsenne tyyneksi ja rauhalliseksi? (1-6; 1=kaiken aikaa; 6=ei lainkaan) 
9. olette tuntenut itsenne masentuneeksi ja alakuloiseksi? (1-6; 1=kaiken aikaa; 6=ei lainkaan) 
10. olette ollut onnellinen? (1-6; 1=kaiken aikaa; 6=ei lainkaan) 
11. olette tuntenut itsenne niin masentuneeksi, ettei mikään piristäisi? (1-6; 1=kaiken aikaa; 6=ei lainkaan) 
Elinvoimaisuuden arviointi (osa-alue 4): 
Kuinka usein viimeisen kuukauden aikana 
12. olette tuntenut itsenne laiskaksi ja saamattomaksi? (1-6; 1=kaiken aikaa; 6=ei lainkaan) 
13. olette tuntenut itsenne energiseksi, aikaansaavaksi tai elinvoimaiseksi? (1-6; 1=kaiken aikaa; 6=ei lainkaan) 
14. olette tuntenut väsymystä, liikarasittuneisuutta, uupumista tai loppuun kulumista? (1-6; 1=kaiken aikaa; 6=ei lainkaan) 
Aktiivisuuden rajoittumisen arviointi (osa-alue 5): 
15. Ympyröikää niiden päivien lukumäärä viimeisten 7 päivän aikana, jolloin teidän täytyi sairautenne vuoksi  
      vähentää niiden asioiden tekemistä, joita tavallisesti teette. (0-7) 
Vuoteeseen rajoittumisen arviointi (osa-alue 6): 
16. Ympyröikää niiden päivien lukumäärä viimeisten 7 päivän aikana, jolloin olitte vuoteen omana koko tai  
      suurimman osan päivästä sairautenne vuoksi. (0-7) 
Yleisen terveydentilan arviointi (osa-alue 7): 
17. Ympyröikää se numero, joka parhaiten kuvaa terveyttänne yleensä viimeisen kuukauden aikana.  
      (0-10; 0=huonoin, jonka voi kuvitella; 10=täysin terve) 
Fyysisen suorituskyvyn arviointi (osa-alue 8): 
Ympyröikää se numero, joka parhaiten kuvaa sitä, miten vaikeaa teidän on viimeisen kuukauden aikana sairautenne vuoksi ollut 
18. tehdä voimaa vaativia tehtäviä, kuten nostaa painavia esineitä, juosta tai urheilla. (1-5; 1=ei vaikeuksia; 5=mahdotonta) 
19. liikkua ja toimia kohtuullisesti, kuten siirtää pöytää tai kantaa ostoksia. (1-5; 1=ei vaikeuksia; 5=mahdotonta) 
20. kävellä ylämäkeä tai nousta muutama kerros portaita. (1-5; 1=ei vaikeuksia; 5=mahdotonta) 
21. nostaa tai kumartua. (1-5; 1=ei vaikeuksia; 5=mahdotonta) 
22. tehdä pieni kävelylenkki ulkona. (1-5; 1=ei vaikeuksia; 5=mahdotonta) 
23. ajaa partaa, pukeutua, kylpeä tai käydä suihkussa. (1-5; 1=ei vaikeuksia; 5=mahdotonta) 
Seksuaalisten toimintojen arviointi (osa-alue 9): 
Ympyröikää se numero, joka parhaiten kuvaa, kuinka hyvin seuraava lause sopii teihin viimeisen kuukauden aikana: 
24. “Olen ollut kiinnostunut seksistä.” (1-5; 1=ei ollenkaan; 5=paljon) 
25. “Luulen, että toiset pitävät minua seksuaalisesti puoleensa vetävänä.” (1-5; 1=ei ollenkaan; 5=paljon) 
26. ”Olen tuntenut itseni seksuaalisesti puoleensa vetäväksi.” (1-5; 1=ei ollenkaan; 5=paljon) 
27.  Oletteko yrittänyt harjoittaa seksuaalista toimintaa, mukaan lukien itsetyydytys ja sukupuoliyhdyntä,  
      viimeisen kuukauden aikana? (1=kyllä; 2=ei)   
      - jos vastasitte “EI”, siirtykää kyselykaavakkeen loppuun. 
Seksuaalisuuden arviointi (osa-alue 10): 
Ympyröikää se numero, joka parhaiten kuvaa, kuinka hyvin seuraava lause sopii teihin viimeisen kuukauden aikana: 
28. “Minun on ollut vaikea kiihottua seksuaalisesti.” (1-5; 1=ei ollenkaan; 5=erittäin hyvin) 
29. “Minun oli vaikea saada tai ylläpitää erektiota.” (1-5; 1=ei ollenkaan; 5=erittäin hyvin) 
30. “Minun oli vaikea saada orgasmi.” (1-5; 1=ei ollenkaan; 5=erittäin hyvin) 
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APPENDIX 4. PSPA-score. 
Performance status: 
Able to carry out normal activity: 0 point 
Restricted in physically strenuous activity but ambulatory and able to carry out light work: 1 point 
Ambulatory and capable of all self-care but unable to carry out any work; up about more than 50 % of waking 
hours: 2 points 
Capable only of limited self-care; confined to bed or chair more than 50% of waking hours: 3 points 
Completely disabled, cannot carry out any self-care; totally confined to bed or chair: 4 points 
 
Pain score: 
None: 0 point 
Mild: 1 point 
Moderately severe: 2 points 
Severe: 3 points 
Intolerable: 4 points 
 
Use of analgesics: 
None: 0 point 
Non-opioids occasionally: 1 point 
Non-opioids regularly: 2 points 
Opioids occasionally: 3 points 
Opioids regularly: 4 points 
> 100% increase in dose of opioids or epidural administration: 5 points 
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Androgen deprivation therapy (ADT) has been 
the standard treatment approach for advanced 
prostate cancer for decades. Despite a good initial 
response rate, many patients are likely to experi-
ence a disease relapse within a few years and 
to experience significant adverse effects with a 
deterioration of quality of life (QoL) from ADT.  
  The FinnProstate Study VII (FPVII) was conduct-
ed as a randomised, controlled, multicenter clinical 
trial to compare intermittent (IAD) and continuous 
androgen deprivation  (CAD) in patients with ad-
vanced prostate cancer in terms of time to progres-
sion, overall survival, cancer-specific survival, time 
to treatment failure, and quality of life.
   No difference emerged in progression or 
survival rates between IAD and CAD among the 
randomised 554 patients. However, QoL seemed 
to be better with IAD than CAD, especially in the 
domains of activity limitation, physical capacity, 
and sexual functioning.
